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Abstract 
 
Effects of morphine and the viral protein Tat on the blood-brain barrier: 
Implications in HIV disease and HAND 
 
Monique Eufemia Maubert 
Co-mentor: Brian Wigdahl, Ph.D. Mentor: Michael R. Nonnemacher, Ph.D.  
 
Many of the pathological observations made in human immunodeficiency 
virus type 1 (HIV-1)-associated neurocognitive disorders (HAND) have been 
attributed to compromise of blood-brain barrier (BBB) integrity. Certain viral 
proteins have been implicated in deregulation of the BBB, including the HIV-1 
transactivator of transcription (Tat). Illicit drug use is also a known confounder of 
disease in HIV-1-infected individuals, and opioid abuse has been reported to 
enhance HIV-1 disease progression in multiple ways, including increased 
incidence and severity of HAND, as compared to non-users. In these studies, a 
well-characterized human brain microvascular endothelial cell line, hCMEC/D3, 
was utilized as an in vitro model of the BBB in order to investigate the 
interactions and consequences of morphine or Tat exposure on the BBB. 
Transport of morphine, without the production of morphine metabolites, across 
the hCMEC/D3 BBB was observed. In addition, changes in the expression of 
mRNA transcripts of tight junction proteins were seen throughout the course of 
hCMEC/D3 exposure to morphine. Furthermore, exposure to repeated 
administrations of morphine resulted in the generation of chemotactic gradients 
xviii 
 
across the in vitro BBB model. When the same model was used to examine if 
recombinant Tat elicited a similar response, it was found that Tat did not affect 
general permeability of the barrier or induce MCP-1 or SDF-1 chemokine 
gradients. Overall, these studies demonstrate that exposure to morphine, and not 
Tat, results in compromise of BBB integrity by inducing alterations in molecular 
expression of key BBB components important to maintaining homeostatic 
regulation of the barrier. 
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1.1. Abstract  
In many individuals, drug abuse is intimately linked with HIV-1 infection. In 
addition to being associated with one-third of all HIV-1 infections in the United 
States, drug abuse also plays a role in disease progression and severity in HIV-
1-infected patients, including adverse effects on the central nervous system 
(CNS). Specific systems within the brain are known to be damaged in HIV-1-
infected individuals and this damage is similar to that observed in drug abuse. 
Even in the era of anti-retroviral therapy (ART), CNS pathogenesis occurs with 
HIV-1 infection, with a broad range of cognitive impairment observed, collectively 
referred to as HIV-1-associated neurocognitive disorders (HAND). A number of 
HIV-1 proteins (Tat, gp120, Nef, Vpr) have been implicated in the etiology of 
pathogenesis and disease as a result of the biologic activity of the extracellular 
form of each of the proteins in a number of tissues, including the CNS, even in 
ART-suppressed patients. In this review, we have made Tat the center of 
attention for a number of reasons. First, it has been shown to be synthesized and 
secreted by HIV-1-infected cells in the CNS, despite the most effective 
suppression therapies available to date. Second, Tat has been shown to alter the 
functions of several host factors, disrupting the molecular and biochemical 
balance of numerous pathways contributing to cellular toxicity, dysfunction, and 
death. In addition, the advantages and disadvantages of ART suppression with 
regard to controlling the genesis and progression of neurocognitive impairment 
are currently under debate in the field and are yet to be fully determined. In this 
review, the individual and concerted contributions of HIV-1 Tat, drug abuse, and 
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ART with respect to damage in the CNS, and how these factors contribute to the 
development of HAND in HIV-1-infected patients is discussed. 
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1.2. Introduction 
The face of the HIV-1 pandemic has evolved from a progressively 
advancing life-threatening disease in the absence of effective therapies to a 
manageable chronic clinical condition with the development of effective 
combination antiretroviral therapy (ART). As a result of more effective therapeutic 
control of HIV-1 disease for prolonged periods of time across the infected 
population, many comorbid conditions have decreased in prevalence while some 
have increased. To this point, there has been a dramatic reduction in the 
prevalence of the more severe forms of HIV-1-associated neurocognitive 
disorders (HAND) including the most severe form, the progressively debilitating 
HIV-1-associated dementia (HAD), that was commonly observed at end-stage 
HIV-1 infection in the absence of effective ART. However, there has been an 
increase in the milder forms of disease encompassing a spectrum of neurological 
symptoms, ranging from a clinically asymptomatic neurocognitive impairment 
(ANI) to more symptomatic presentations of cognitive impairment (Wadia et al., 
2001; Antinori et al., 2007). The mechanisms by which HIV-1 infection promotes 
neuropathogenesis is based on viral entry into the central nervous system (CNS) 
early during the course of infection by breaching of the blood-brain barrier (BBB) 
followed by a series of events that center around the neurotoxic activity of a 
number of HIV-1 proteins including gp120, Tat, Vpr, and likely others, along with 
alterations in CNS homeostasis that involve the metabolic integrity of the blood-
brain barrier and metabolism of astrocytes, perivascular macrophages, and 
resident microglial cells. These are all events that lead to disruption of neuronal 
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physiology and increasing levels of death in this critical cell population (Toborek 
et al., 2005; Rao et al., 2014) (Figure 1.1.). 
HIV-1 proteins (gp120, Tat, Vpr, and Nef) are released from infected cells, 
either through secretion or after lysis of the cell, throughout the course of 
infection and perpetuate an ongoing burden in a number of tissues, including the 
CNS, resulting in toxicity and damage, regardless of ART (Wang et al., 2006; 
Strazza et al., 2011; Gresele et al., 2014). Of these, Tat (the transactivator of 
transcription) is a viral protein, 101 amino acids in length, known to be made and 
secreted early and continuously by HIV-1-infected cells in the CNS throughout 
infection and has been implicated in mediating and altering the functions of 
several host factors, disrupting the molecular and biochemical balance of 
numerous pathways, thus contributing to cellular toxicity, dysfunction, and death 
(Ensoli et al., 1993; Chang et al., 1997; Rappaport et al., 1999; Li et al., 2009; 
Ganief et al., 2017). Tat functions as the primary viral transcription factor, binding 
and altering the function of a number of cellular players in the host transcriptional 
machinery (Frankel and Young, 1998; Friedrich et al., 2011; Ramakrishnan et al., 
2012). The transactivator has been shown to consist of six domains that have 
been linked experimentally to a number of Tat-mediated consequences, including 
both intracellular- and extracellular-triggered events (Jeang et al., 1999; 
Debaisieux et al., 2012; Li et al., 2012). 
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Figure 1.1. The blood-brain barrier (BBB) under normal and pathologic 
conditions. The BBB is a network of microvasculature composed primarily of 
endothelial cells, astrocytes, and pericytes and functions as a selective, semi-
permeable barrier, thus maintaining central nervous system (CNS) homeostasis 
and regulating communication between the CNS and the periphery. The semi-
permeable nature of the BBB, including cellular transmigration across the barrier, 
is regulated through the expression of tight junction complexes, adherens 
junction complexes, and cell adhesion molecules. (A) Under normal homeostatic 
conditions, CNS component cells of the BBB, as well as CNS immune regulators, 
are healthy and BBB integrity is properly maintained. During infection or other 
assault, activation of select CNS cells results in a pro-inflammatory environment, 
yielding cellular, and tissue injury, including altered expression of cell adhesion 
molecules, adherens junction proteins, and tight junction proteins, resulting in 
BBB compromise. (B) During HIV-1 infection, Tat protein mediates detrimental 
effects on specific cells, including CNS component cells and CNS immune 
regulators, altering the activation status, and molecular profiles of several cell 
types, resulting in a pro-inflammatory environment, and associated damage to 
the BBB. It is theorized that Tat is thus an important viral factor in the incidence 
and progression of HAND in HIV-1-infected patients. 
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Figure 1.1. 
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 Extracellular Tat has been shown to adversely impact a number of cell 
types, exhibiting particularly negative effects on cells of the CNS, including 
neurons, astrocytes, brain microvascular endothelial cells (BMEC), and microglia, 
as well as macrophages. Extracellular Tat protein is quickly and efficiently taken 
up by uninfected neurons (Kolson et al., 1994) and astrocytes (Ma and Nath, 
1997) exerting direct and indirect consequences on these and neighboring CNS 
cells. These harmful outcomes include neuronal toxicity and dysfunction via 
mitochondrial membrane hyperpolarization and aberrant synaptic signaling 
(Chauhan et al., 2003; Norman et al., 2007), altered dendritic arborization and 
morphology (Bruce-Keller et al., 2003; Aprea et al., 2006), and deregulation of 
epigenetic modulators (Saiyed et al., 2011). In addition, Tat exposure has also 
been shown to mediate apoptosis (Acheampong et al., 2002; Kim et al., 2003), 
alter molecular permeability (András et al., 2003; Mahajan et al., 2008; Gandhi et 
al., 2010; Mishra and Singh, 2014), and enhance secretion of pro-inflammatory 
cytokines (Acheampong et al., 2002; Woollard et al., 2014) from BMECs, a 
primary component of the BBB. 
These issues are further complicated by naturally occurring comorbid 
diseases and conditions, the prevalence of which appear to be accelerated or 
augmented in HIV-1-infected patients, including increased permeability of the 
BBB and an enhanced chronic pro-inflammatory state in the host, as compared 
to the general population (Weiss et al., 2009; Scott et al., 2011; Pirrone et al., 
2013; Nasi et al., 2014). Moreover, host genetics have been shown to play an 
irrefutable role in the grand scheme of disease severity (if not incidence) and rate 
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of progression of neurocognitive deficits in all patients, regardless of HIV-1 
status, which is additionally confounded by lifestyle, including but not limited to 
diet and exercise habits, medicinal intake, therapy, and indulgence in 
recreational drugs (Nath et al., 2002; Liu et al., 2012; Nasi et al., 2014; Smith et 
al., 2014). 
Across four decades of increasingly effective therapies, the HIV-1 protein 
Tat has been shown to play an important role in viral replication and 
pathogenesis as both an intracellular and extracellular protein. At present, in 
ART-naïve patients experiencing varying degrees of immunological control, as 
well as patients well-suppressed by ART, and patients experiencing less than 
ideal responses to ART for numerous reasons, Tat has continued to be a focus 
as a protein that may be produced and released from cells in the absence or 
presence of infectious virus production (Falkensammer et al., 2007; Mediouni et 
al., 2012) with subsequent impact on immunologic and neurologic function, to the 
detriment of the host. It has been suggested that this may be one of the 
underlying mechanisms of HAND (involving Tat production and release, leading 
to alterations in inflammatory molecule production by interacting with cellular 
gene promoters and cellular receptors to induce apoptosis and cell death) 
(Rappaport et al., 1999; Bagashev and Sawaya, 2013). With respect to drugs of 
abuse, it is widely known that drug use is widespread in the HIV-1-infected 
community. It has also been shown in a number of HIV-1-infected patient cohorts 
that there are preferences with respect to the type of drugs used that have been 
associated with the region of the United States or part of the world wherein a 
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patient resides. Consequently, these preferences complicate the ability to 
understand how select drugs interact with HIV-1 and its gene products. 
Furthermore, regional differences in substance abuse profiles, and 
methodologies used to define the types of substances used (e.g., self-reporting, 
medical history, blood and/or urine analysis, as well as hair follicle analysis) 
further complicates studies focused on understanding the use of any single 
substance (Levine et al., 2014; Holtz et al., 2015; Rosinska et al., 2015; Atluri 
2016). These considerations are further impacted by the fact that a majority of 
HIV-1-infected individuals can test positive at any given clinical visit for three or 
more substances that often include tobacco, alcohol, cocaine, heroin, cannabis, 
and many others (Nishijima et al., 2013; Chang et al., 2014; Huang et al., 2014; 
Ti et al., 2014). Given these considerations, understanding regional drug use 
demographics, frequency of use, and blood levels are important factors to 
consider in the data analysis, phase of experimentation, and in formulating 
conclusions. 
1.3. Tat and Drugs of Abuse in the CNS 
Clinical reports, as well as experiments involving both in vitro and in vivo 
investigations, have been instrumental in defining the factors and pathways 
implicated in neurocognitive compromise and their involvement in HAND. Drug 
use is a well-known confounding factor that contributes to neurocognitive 
impairment and the development of dementia. Within HIV-1-infected populations, 
the widespread use of recreational drugs (including opiates, amphetamines, 
cocaine, and ethanol) has been shown to adversely impact the incidence and 
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severity of HAND (as well as other HIV-1-associated diseases), as compared to 
non-users (Nath et al., 2002; Green et al., 2004; Sharma and Ali, 2006; Theodore 
et al., 2007; Silverstein et al., 2011; Hauser et al., 2012; Nair and Samikkannu, 
2012; Rao et al., 2014). In particular, the HIV-1 Tat protein has been identified, 
both in vitro and in vivo, to perform in an additive or synergistic manner in a 
number of experimental Tat—drug abuse co-exposure models (Nath et al., 2002; 
Li et al., 2009). 
1.3.1. Tat and Opiates 
Of the four opioid receptors currently described in the literature (i.e., delta, 
kappa, mu, and opioid-receptor-like1), the mu opioid receptor is the most 
common target of currently available opioids, both in the clinic and on the streets, 
and is expressed in many tissues throughout the body including the CNS (Al-
Hasani and Bruchas, 2011; Feng et al., 2012). Morphine, which is administered 
to patients as part of many pain management regimens, is also a metabolic 
derivative of heroin, and binds the mu opioid receptor with high affinity (Bell, 
2014). The singular and synergistic effects of HIV-1 Tat and opiates (specifically 
morphine) on select cells of the CNS have been demonstrated experimentally 
both in vitro and in vivo, providing biochemical and cellular correlates for 
observed clinical manifestations of HAND. 
Utilization of an in vitro BBB model comprised of primary human BMEC 
(hBMEC) and astrocytes in co-culture demonstrated a decrease in barrier 
tightness coupled to a parallel increase in immune cell transmigration as a result 
of either Tat or morphine exposure, and BBB permeability was further 
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exacerbated by co-exposure to both agents simultaneously (Mahajan et al., 
2008). Exposure to either morphine or Tat also resulted in diminished mRNA 
expression of the tight junction proteins (TJP) occludin and zona occludens-1 
(ZO-1), and a concomitant increase in the cell adhesion molecule (CAM) 
junctional adhesion molecule-2 (JAM-2) mRNA expression in hBMEC, and these 
events were amplified by co-exposure to both compounds (Mahajan et al., 2008). 
Mono-exposure of the hCMEC/D3 BMEC line to Tat also resulted in the 
enhanced nuclear translocation of ZO-1 within exposed cells (Zhong et al., 
2012), and Tat also downregulated mRNA and protein expression of occludin of 
exposed primary hBMECs (Xu et al., 2012). In addition, the proliferative capacity 
of primary murine oligodendroglial progenitors was impeded (Hahn et al., 2012), 
and activation of caspase-3 in primary murine oligodendrocytes was augmented 
(Hauser et al., 2009), by exposure to either morphine or Tat, and these effects 
were further potentiated by co-exposure. Caspase-3 activation and apoptosis 
were also upregulated in primary murine glial precursor cells by mono-exposure 
to either Tat or morphine, in vitro (Buch et al., 2007). 
Primary murine astrocytes or microglia (Pu et al., 2003; El-Hage et al., 
2005, 2008; Bokhari et al., 2009), as well as human U373 MAGI astrocytes and 
primary human monocytes (Siddappa et al., 2006) exposed to Tat, and primary 
hBMEC exposed to Tat or morphine (Mahajan et al., 2008) enhanced secretion 
and mRNA transcript expression of a number of pro-inflammatory cytokines 
(including IL-1B, IL-6, IL-8, MCP-1, and TNFα), which was further augmented in 
both astrocytes and BMEC by co-exposure of cells with both Tat and morphine. 
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Furthermore, exposure of primary murine microglia to either morphine or Tat 
protein alone prompted nominal increases in expression of CCR5, and 
differences in morphology and activation status (Turchan-Cholewo et al., 2008; 
Bokhari et al., 2009), as well as aberrant regulation and expression of opioid 
receptors (Turchan-Cholewo et al., 2008; Bokhari et al., 2009), which were all 
exacerbated by co-exposure (Turchan-Cholewo et al., 2008; Bokhari et al., 
2009). In addition, direct exposure to either morphine or Tat enhanced migration 
of primary murine microglia (Suzuki et al., 2011), while treatment with 
conditioned media from Tat- or morphine-exposed astrocytes also enhanced 
migration of the N9 murine microglia cell line (El-Hage et al., 2006) in vitro. 
Notably, this escalation in microglial cell migration was further increased by direct 
co-exposure to morphine and Tat (Suzuki et al., 2011) or to media derived from 
co-exposed astrocytes (El-Hage et al., 2006). 
In vitro exposure to Tat increased intracellular sodium- and calcium-ion 
concentrations in primary murine striatal neurons (Fitting et al., 2014), as well as 
mitochondrial membrane depolarization in primary human and murine neurons, 
as well as in the SHSY5Y human neuronal cell line (Malik et al., 2011; Fitting et 
al., 2014), and these effects were dramatically amplified by co-exposure with 
morphine, demonstrating increased Tat-mediated neurotoxicity in the presence of 
opiates. Exposure to Tat or morphine alone also significantly decreased γ-
aminobutyric acid (GABA) release/neurotransmission from primary murine striatal 
slices, which was further decreased by co-exposure (Xu and Fitting, 2016). 
Additionally, an increase in apoptosis, as well as enhanced generation of reactive 
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oxygen species (ROS) by exposure to either Tat or morphine alone, was further 
enhanced by co-exposure in both primary human neurons and in SHSY5Y cells 
(Malik et al., 2011; Suzuki et al., 2011). Interestingly, the neurotoxic 
consequences of co-exposure were attenuated in primary murine neurons in the 
presence of exogenous fractalkine treatment (Suzuki et al., 2011), a 
neuroprotective chemokine shown to prevent apoptosis of Tat-exposed primary 
rat neurons in vitro (Tong et al., 2000) and constitutively produced in human 
brain tissue (Wang et al., 2006), but downregulated by co-exposure to Tat and 
morphine (Suzuki et al., 2011), suggesting the potential for adjunctive fractalkine-
enhancing therapy in HIV-1-infected patients with HAND. 
With respect to in vivo experimental results, utilization of a doxycycline-
inducible Tat-transgenic mouse model under control of the human glial acidic 
fibrillary protein (GFAP) promotor (allowing for brain-specific expression of Tat) 
was shown to exhibit a higher percentage of activated microglia and 
macrophages, as well as astrocytes, and this activation was further potentiated 
by morphine treatment (through the implantation of a slow-release subcutaneous 
pellet; Bruce-Keller et al., 2008). Furthermore, neurons from Tat-transgenic mice 
displayed an approximately 10-fold upregulation of caspase-3 expression, which 
was additionally boosted by treatment with morphine (Bruce-Keller et al., 2008; 
Hauser et al., 2009). In vivo induction of Tat in these transgenic mice also 
instigated aberrant morphological changes in oligodendrocytes, including 
diminished length and number of cellular processes, as well as the presence of 
dendrite swelling and phenotypically abnormal cell bodies (Hauser et al., 2009); 
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curiously, morphine exposure alleviated Tat-mediated effects on process lengths, 
however all other aberrations were exacerbated. Both induction of Tat in 
transgenics and subcutaneous injection of morphine in Tat-negative mice 
resulted in decreased proliferative capacity of brain cells, in general, and of 
undifferentiated and oligodendroglial progenitors, in specific, which was 
additionally reduced in morphine-treated Tat-transgenic mice (Hahn et al., 2012). 
Behaviorally, subcutaneous injection of morphine in non-transgenic mice and 
induction of Tat in transgenic mice individually slowed reaction times and 
compromised performance of exposed animals in nociception and balance 
testing (Fitting et al., 2012), demonstrating independent effects of these 
compounds that can combine to adversely impact general neuro-functional 
outcomes in HAND. 
1.3.2. Tat and Cocaine 
Cocaine highjacks dopamine signaling pathways in vivo by binding up the 
dopamine transporter in the synapse, thereby causing increased localized 
concentration of dopamine and heightened stimulation of receiving post-synaptic 
neurons, thus exerting its effects which result in the well-known “high” 
experienced by users (Nestler, 2005; Blaylock and Nader, 2012). The 
consequences of in vitro exposure of CNS component cells to mono- or co-
exposure to Tat and cocaine has yielded interesting observations with 
implications for CNS disease manifested in cocaine-using patients with HAND. 
Studies have indicated that exposure of primary rat neurons to Tat alone 
resulted in a decrease in mitochondrial membrane potential and cellular viability, 
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as well as a concomitant increase in the generation of intracellular ROS and 
enhanced protein oxidation, all of which were significantly potentiated by co-
exposure to cocaine, in vitro (Aksenov et al., 2006). In addition, mono-exposure 
of an in vitro BBB primary human BMEC-astrocyte co-culture model to Tat or 
cocaine resulted in increased BBB compromise and permeability, including an 
increase in monocyte transmigration across the in vitro barrier, as well as 
alterations in TJP (ZO-1) and CAM (JAM-2) expression (Gandhi et al., 2010); 
observations which were further exacerbated by exposure to both compounds in 
tandem. 
In vivo, both acute (involving a 1-day interval) and chronic (involving 7–14-
day intervals) exposure to either cocaine by intra-peritoneal (IP) injection, or 
intra-accumbal (IA) injection of Tat, differentially deregulated the generation of 
extracellular dopamine metabolites in the brains of exposed rats, and Tat-
mediated effects on metabolite levels were further exacerbated by co-exposure 
to cocaine (Ferris et al., 2010). IP injection of rats with cocaine alone enhanced 
neuronal excitability, however, bathing of ex vivo pre-frontal cortex pyramidal 
neurons from animals exposed in vivo to chronic (14 days of exposure) cocaine 
with exogenous Tat further augmented neuronal excitability (Napier et al., 2014), 
providing credence to an interactive role of cocaine and Tat in observed 
neurocognitive impairment in cocaine-using HIV-1-infected patients. 
Behaviorally, cocaine mono-exposed animals (but not Tat co-exposed 
animals) displayed a higher level of activity than Tat-only or vehicle-controls, 
demonstrating diverging behavioral consequences of cocaine use in the context 
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of HIV-1 infection (Ferris et al., 2010). Importantly, pre-exposure of rats to IA-
injected Tat amplified the effects of an acute 1-day exposure to intravenous (IV) 
cocaine, but mitigated the effects of a chronic 14-day exposure of cocaine to 
sensitization, highlighting differences between acute vs. chronic cocaine use 
during the course of in vivo Tat exposure (Harrod et al., 2008). Furthermore, 
utilization of a brain-specific doxycycline-inducible Tat-transgenic mouse model 
under control of the murine GFAP promotor yielded several-fold increases in 
cocaine-conditioned place preferences by Tat-induced mice after subcutaneous 
injection of cocaine [cocaine-conditioned place preference being a correlate for 
the rewarding effects of addictive behavior, defined by the amount of time an 
animal spends in the cocaine-associated chamber as compared to the pre-
cocaine baseline] (Paris et al., 2014). This observation provides evidence that 
CNS expression of Tat is capable of intensifying cocaine-additive behaviors in 
vivo. 
1.3.3. Tat and Amphetamines 
Amphetamines function similarly to cocaine in their ability to interfere with 
dopamine signaling pathways, thus resulting in a build-up of dopamine in the 
synapse and over-stimulation of post-synaptic neurons resulting in the 
characteristic “high” experienced by users (Calipari and Ferris, 2013). Both in 
vitro and in vivo experiments have been conducted in order to elucidate the 
consequences of exposure to Tat and/or amphetamines on relevant cells of the 
CNS, and how these may be involved in the HAND outcomes observed in HIV-1-
infected patients who use amphetamines. 
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In vitro studies demonstrate susceptibility of primary rat neurons to 
apoptosis by exposure to Tat (Theodore et al., 2006a), and of SHSY5Y cells by 
treatment with methamphetamine (Qi et al., 2011), with cellular viability further 
compromised by co-exposure to both agents (Maragos et al., 2002; Theodore et 
al., 2006a; Qi et al., 2011). Co-exposure of primary human neurons to Tat and 
methamphetamine also increased cell death, which was accompanied by a 
decrease in mitochondrial membrane potential (Maragos et al., 2002) and 
characterized by a concomitant increase in the presence of autophagosomes (Qi 
et al., 2011). In addition, exposure of primary human neuron-astrocyte co-
cultures to methamphetamine alone also enhanced secretion of matrix 
metalloproteinase-1 (MMP-1), whereas exposure to Tat upregulated secretion of 
both MMP-1 and MMP-2 (Conant et al., 2004), proteases capable of degrading 
select extracellular matrix components, thus compromising BBB integrity. 
Transfection of the U87MG human astrocyte cell line with Tat plasmid or 
exposure of cells to methamphetamine inhibited beta-catenin signaling, which 
was further diminished by co-exposure to both compounds (Sharma et al., 2011). 
Furthermore, co-transfection of CHME-5 human microglia cells with LTR- and 
Tat-containing plasmids exposed to methamphetamine augmented HIV-1 LTR 
transactivation by Tat, as well as NFκB nuclear translocation, in a dose-
dependent manner (Wires et al., 2012), underscoring a potential cooperative 
relationship of amphetamines and Tat in enhancement of viral replication in HIV-
1-infected patients who use amphetamines. 
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In vivo experiments have demonstrated upregulated expression of a 
number of pro-inflammatory cytokines in response to Tat and amphetamine 
exposure. Notably, both TNFα secretion (Flora et al., 2003; Theodore et al., 
2006a,b; Liu et al., 2014) and mRNA transcript expression (Flora et al., 2003; 
Theodore et al., 2006a,b; Liu et al., 2014) were upregulated in models utilizing 
different routes of Tat administration [including intra-striatal (IS) injection (Flora et 
al., 2003; Theodore et al., 2006a,b; Liu et al., 2014), and intra-nigral (IN) micro-
injection (Flora et al., 2003; Theodore et al., 2006a,b; Liu et al., 2014) in rats, and 
intra-hippocampal (IH) injection in mice (Flora et al., 2003; Theodore et al., 
2006a,b; Liu et al., 2014)], and TNFα levels were further potentiated by IP 
injection with methamphetamine in all models examined in these studies (Flora et 
al., 2003; Theodore et al., 2006a,b; Liu et al., 2014). In addition, IL-1B expression 
was also increased by IH injection of Tat in mice (Flora et al., 2003; Theodore et 
al., 2006a,b; Liu et al., 2014) and by IN injection of Tat in rats (Flora et al., 2003; 
Theodore et al., 2006a,b; Liu et al., 2014), and further enhanced in both models 
by IP injection with methamphetamine (Flora et al., 2003; Theodore et al., 
2006a,b; Liu et al., 2014). Moreover, IS administration of Tat coupled with IP co-
exposure of rats to methamphetamine also augmented whole-tissue protein 
expression of IL-1α and MCP-1 (Flora et al., 2003; Theodore et al., 2006a,b; Liu 
et al., 2014). This deregulation of immune modulators was also accompanied by 
a concomitant downregulation of serotonin, dopamine, and dopamine metabolite 
levels in the brains of co-exposed animals (Maragos et al., 2002; Cass et al., 
2003; Theodore et al., 2006a; Liu et al., 2014). Additionally, in vivo exposure of 
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mice to either IH Tat or IP methamphetamine induced increases in oxidative 
stress, enhanced DNA-binding of select redox-responsive transcription factors 
(e.g., AP-1, CREB, and NFκB), and upregulated CAM (e.g., intercellular 
adhesion molecule-1; ICAM-1) expression, which were all potentiated by co-
exposure (Flora et al., 2003). With respect to behavior, IN Tat or IP 
methamphetamine alone impaired the performance of rats in balance and 
locomotor tests, which were worsened in co-injected animals (Liu et al., 2014), 
implying molecular cooperation between Tat and amphetamines in the enhanced 
cognitive deterioration observed in HIV-1-infected patients who use 
amphetamines, thereby highlighting the need for improved interventions and 
treatment options. 
1.3.4. Tat and Ethanol 
The pleiotropic effects of ethanol have long been appreciated in the clinic 
and also reported in in vitro and animal model studies. The multifaceted 
consequences of ethanol exposure have also been extensively examine in the 
CNS, where ethanol has been shown to have multiple (sometimes polarizing) 
effects on a number of neurotransmitter receptors and their respective pathways, 
including but not limited to aberrant modulation of γ-aminobutyric acid type A 
(GABA-A) receptors and N-methyl-D-aspartate (NMDA) receptors in the brain 
(Davies, 2003; Paul, 2006). The role of co-exposure to exogenous Tat protein 
and ethanol on CNS cell populations cultured in vitro and further examined in 
vivo infer adverse consequences for alcohol-dependent HIV-1-infected patients. 
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In vitro experimentation involving exposure of primary hBMEC to 
exogenously applied Tat showed elevated secretion of TNFα from, and 
substantially increased apoptosis of, this primary cell population (Acheampong et 
al., 2002) and these effects were potentiated by co-exposure of hBMEC to 
ethanol (Acheampong et al., 2002; Brailoiu et al., 2006). In addition, Tat also 
enhanced intracellular calcium accumulation and apoptosis in exposed primary 
rat cortical neurons, which was further augmented in the presence of both 
compounds (Acheampong et al., 2002; Brailoiu et al., 2006), demonstrating 
profound cytotoxic effects of Tat on CNS cells that were accentuated in the 
presence of ethanol. 
Ex vivo mono- and co-exposure of primary rat hippocampal explants to 
Tat and ethanol provided additional evidence of Tat-mediated toxicity being 
augmented in the presence of ethanol (Self et al., 2004), suggesting a tangible 
role for the interaction of Tat and ethanol in the development of HAND in HIV-1-
infected patients; this was further corroborated by behavioral reports of in vivo 
studies wherein rats chronically exposed to ethanol (involving oral dosing three 
times a day for four consecutive days) demonstrated significant withdrawal-
associated symptoms, which were potentiated by IH injection with Tat (Self et al., 
2009). Moreover, co-exposed animals exhibited sustained decreases in task 
performance in water maze testing as compared to mono-exposed and control 
animals (Self et al., 2009), indicating more severe cognitive decline in the 
presence of Tat and exposure to ethanol. These behavioral results in well 
characterized animal models were further supported by clinical observations 
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demonstrating more profound impairment in HIV-1-infected patients with a history 
of alcohol abuse as compared to HIV-1-positive non-alcohol-dependent or HIV-1-
negative participants, regardless of alcohol abuse history (Green et al., 2004). 
Biochemically, in vivo co-exposure of mice to IP injection of ethanol or IH 
injection of Tat resulted in elevation of ICAM-1 mRNA expression in brain tissue 
(Flora et al., 2005). In addition, exposure to either ethanol or Tat individually 
triggered increases in oxidative stress and proinflammatory cytokines (IL-1B, 
MCP-1, and TNFα), that were augmented in the hippocampus and corpus 
striatum of co-exposed mice (Flora et al., 2005), demonstrating an amplification 
of Tat-mediated immune deregulation in the brain by ethanol. Tat-transgenic 
mice (in which Tat was constitutively expressed under control of the simian virus 
40 promoter) also exhibited significant defects in innate immune function (as 
compared to non-transgenic animals), and these were further exacerbated by 
either chronic oral daily dosing with ethanol for 7 days (Prakash et al., 1998a,b) 
or by acute dosing of one IP injection with ethanol (Prakash et al., 1998a,b). 
Moreover, chronic exposure of Tat-transgenic mice to ethanol and/or the drug 
azidothymidine (AZT) diminished in vivo hematopoiesis, as compared to non-
exposed animals (Prakash et al., 2001), implying enhanced toxicity of cells of the 
hematopoietic system co-exposed to Tat, ethanol, and/or AZT. 
1.3.5. Tat and Cannabinoids 
The endocannabinoid system is modulated by the expression of two 
primary cannabinoid receptors, termed CB1 and CB2, which demonstrate 
differential enriched expression in different tissues, with CB1 receptors 
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expressed primarily in the CNS and CB2 receptors expressed mostly on various 
immune cells (Pertwee, 2006; Mackie, 2008). In contrast to the predominantly 
negative outcomes of most recreational drug use, there is evidence to suggest a 
positive role for the use of cannabinoids (or simply the activation of cannabinoid 
receptors), particularly within the context of HIV-1 infection (Purohit et al., 2014). 
Reports involving the use of in vitro experimental systems have 
demonstrated the effects of co-exposure of cannabinoids with HIV-1 Tat protein 
in cells relevant to the CNS. Exogenous Tat exposure of the U-937 human 
monocyte cell line (which express CB2, but not CB1) enhanced in vitro 
transmigration of these cells across a porous polycarbonate transwell insert 
(Raborn and Cabral, 2010; Raborn et al., 2014), as well as adhesion to 
extracellular matrix (ECM) proteins (Raborn and Cabral, 2010; Raborn et al., 
2014), while pre-treatment of the monocytic cells with cannabinoids blocked 
these Tat-mediated transmigration and cellular adhesion effects (Raborn and 
Cabral, 2010; Raborn et al., 2014). Morphologically, exposure to Tat induced U-
937 cells to adopt a more adherent, activated macrophage-like phenotype, 
whereas co-exposure with cannabinoids inhibited this phenotypic 
metamorphosis, thus cells maintained a non-activated monocyte-like phenotype 
(Raborn et al., 2014). At the molecular level, Tat also enhanced expression of the 
CAM B1-integrin on U-937 cells, an effect abrogated by co-treatment with 
cannabinoids (Raborn et al., 2014). 
Exposure of the C6 rat glial cell line (which express both CB1 and CB2) 
with Tat yielded an increase of reactive nitrogen species (RNS) and related 
25 
 
enzymes, which was diminished by co-exposure with a cannabinoid mimetic 
(Esposito et al., 2002). In addition, Tat exposure increased GFAP mRNA and 
protein expression in primary human Muller glia (which also express both 
cannabinoid receptors), and this expression was reduced by co-exposure with 
endocannabinoids, in vitro (Krishnan and Chatterjee, 2014). Furthermore, a Tat-
induced decrease in glial viability was rescued by co-exposure with either a 
cannabinoid mimetic (Esposito et al., 2002) or endocannabinoids (Krishnan and 
Chatterjee, 2014). 
Immunologically, Tat-mediated upregulation of a panel of pro-inflammatory 
cytokines (e.g., IL-1B, IL-2, IL-8, IL-12, IL-15, IFNγ, G-CSF, M-CSF, and TNFα) 
in primary human Muller glia was dampened by co-exposure to 
endocannabinoids (Krishnan and Chatterjee, 2014); remarkably, upregulation of 
anti-inflammatory cytokine secretion (e.g., IL-10 and TGF-β) by Tat was 
concomitantly enhanced in the presence of endocannabinoids (Krishnan and 
Chatterjee, 2014), providing evidence that cannabinoids skew cytokine 
production toward an anti-inflammatory profile, and demonstrating a possible use 
of cannabinoids in the treatment of select pro-inflammatory conditions, including 
HIV-1-associated diseases such as HAND. In support of in vitro studies, a clinical 
trial aimed at determining the effects of cannabinoids in HIV-1-infected patients 
on ART demonstrated that treatment with cannabinoids decreased serum viral 
RNA levels, increased CD4+ and CD8+ T-cell counts, and stimulated weight gain 
in HIV-1-positive patients on protease inhibitors, implying an effective adjunctive 
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therapeutic use of cannabinoids in HIV-1-infected patients on ART (Abrams et 
al., 2003). 
1.4. ART and Drugs in HAND 
The development of more effective combinations of ART over the past 
decade has been instrumental in the conversion of HIV-1 infection from a rapidly 
progressing immunodeficiency into a chronic, manageable condition with the 
development and deployment of an ever-increasing number of antiretroviral 
therapeutic agents in most industrialized countries. ART has played a critical role 
in the reduction of HIV-1 viral loads, boosting of CD4+ T-cell counts, and wide-
ranging mitigation of the most severe symptomology associated with many of the 
comorbidities associated with HIV/AIDS in the earliest era of the pandemic 
(Wang et al., 2006; Gresele et al., 2014). These benefits were emphasized by 
early clinical reports of declines in incidences and severity of neurocognitive 
deficits and disturbances in HIV-1-infected patients using more effective ART 
regimens, as compared to patients on mono-therapy or no therapy (Ferrando et 
al., 1998; Price et al., 1999; Tozzi et al., 1999; Cohen et al., 2001). Subsequent 
analyses, however, comparing clinical data before and after the implementation 
of more effective combination therapeutic strategies have clearly demonstrated 
that although the overall severity of HAND exhibited in patients has declined with 
the introduction of combination therapeutic approaches (with a skewing of HAND 
symptoms to the less severe end of the spectrum) the incidence of HAND has 
not decreased (Cysique et al., 2004; Robertson et al., 2007; Tozzi et al., 2007; 
Heaton et al., 2010, 2011; Simioni et al., 2010; Cysique and Brew, 2011). 
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Arguably, the benefits of viral load reduction and improvement of the 
general health state of HIV-1-infected patients comes at the cost of toxic side-
effects characteristic of current ART options (Meeker et al., 2014). Surprisingly, 
some HIV-1-infected patients prescribed ART regimens with a greater CNS 
penetration effectiveness (CPE) ranking exhibited more impaired performance on 
neurocognitive assessments, as compared to patients on regimens with a poorer 
CPE ranking, despite improved suppression of viral replication in the CNS 
compartment (Marra et al., 2009). In contrast, patients in a different cohort on 
ART with high CPE ranking demonstrated improved neurocognitive testing 
scores, but only if their ART regimen consisted of more than three drugs overall 
(Smurzynski et al., 2011). Interestingly, clinical data demonstrate progressive 
and sustained improvements in performance on neurocognitive assessments in 
HIV-1-infected patients who voluntarily discontinued long-term ART (Robertson 
et al., 2010). These results were observed even with continued HIV-1 viral RNA 
and protein production (including Tat), persistent aberrant immune activation, 
and enhanced amyloidosis in patients whose HIV-1 infection was considered 
successfully managed on ART (Falkensammer et al., 2007; Clifford et al., 2009; 
Yukl et al., 2009; Giunta et al., 2011; Heaton et al., 2011; Mediouni et al., 2012; 
Gresele et al., 2014; Smith et al., 2014), underscoring the demand for more 
comprehensive, improved, and adjunctive therapies in HIV-1-infected patients. 
An important clinical consideration with regard to therapy regimens, 
regardless of toxicity, is the potential for non-adherence to ART, particularly in 
drug-abusing HIV-1-infected patients, who demonstrate higher non-adherence as 
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compared to non-drug-abusing cohorts (Kamarulzaman and Altice, 2015; Kumar 
et al., 2015). This observation calls for the development of additional intervention 
strategies in these higher-risk populations, such as methadone maintenance 
therapy in opioid abusers, which has demonstrated promise in an increase in 
adherence compliance in these difficult-to-monitor populations (Lappalainen et 
al., 2015). Further confounding the HIV-1-infected patient treatment paradigm is 
the potential for pharmacological interactions between ART and various 
recreational drugs, as well as other prescription drugs or over-the-counter drugs; 
interactions which are often unrecognized, but commonly require dosing 
adjustments (Kumar et al., 2015; Stolbach et al., 2015). 
The limitations of current ART to eliminate HIV-1 from patients despite 
long-term therapy or early therapeutic intervention also highlights the importance 
of HIV-1 reservoirs that remain unaffected by even the most rigorous therapeutic 
regimens. The recently reported viral rebounds of the so-called “Mississippi 
Baby” (Persaud et al., 2013; NIAID, 2014; Rainwater-Lovett et al., 2015), the 
“Boston Patients” (Henrich et al., 2013), and the VISCONTI cohort (Sáez-Cirión 
et al., 2013) demonstrate an ineffectiveness of currently available ART to 
penetrate and minimize or possibly eliminate HIV-1 reservoirs, which some 
speculate to include a number of resident CNS cell populations, including but not 
limited to perivascular macrophages, microglia, and astrocytes (Liner et al., 2010; 
Archin et al., 2014; Gray et al., 2014; Fois and Brew, 2015; Joseph et al., 2015; 
Gray et al., 2016). 
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1.5. Conclusions 
HIV-1 Tat mediates several detrimental consequences to multiple CNS 
cell populations, both in vitro and in vivo, including neurotoxicity, aberrant cellular 
activation, and endothelial dysfunction (Figure 1.1.). These pathologies have 
been anticipated based on the spectrum of observed HAND manifested in HIV-1-
infected patients (Figure 1.2.). Clinically, Tat mRNA and protein has been 
consistently found in the brains of HIV-1 encephalitis (HIVE) patients, where it 
has been linked to a number of types of neurological impairment, including 
dementia (Hofman et al., 1994; Hudson et al., 2000; Chang et al., 2011). Further 
confounding these pathologies, genetic signatures identified within and between 
HIV-1 subtypes demonstrate specific phenotypic features associated with the 
incidence and severity of HAND, including molecular and functional compromise 
of the BBB (Spira et al., 2003; McArthur, 2004; Liner et al., 2007; Li et al., 2012; 
Bertrand et al., 2013; Dahiya et al., 2013). In addition, investigations by multiple 
groups have demonstrated that HIV-1 Tat is indeed produced despite clinically 
successful ART in well-controlled HIV-1-infected patients (Falkensammer et al., 
2007; Mediouni et al., 2012). Given these observations and the fact that Tat-
exposed animals exhibit many of the neurological characteristics associated with 
HIV-1-infected patients, these studies emphasize the need for improved 
therapies aimed at the direct neutralization of Tat and/or the mitigation of Tat-
mediated effects in HIV-1-infected patients. These may include small molecule   
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Figure 1.2. Outcomes of HIV-1 Tat interactions with various recreational 
drugs and antiretroviral therapy (ART). (A) Tat or drug use alone are capable 
of mediating significant damage to the CNS, however, these effects are often 
exacerbated in the context of comorbid illicit drug use in HIV-1-infected patients. 
In vitro experiments have provided vital information on the multiple molecular-, 
cellular-, and tissue-altering effects of Tat in the absence and presence of drugs 
of abuse, including opiates (op), cocaine (coc), amphetamines (amp), and 
ethanol (eth). One notable exception appears to be in the case of cannabinoids, 
which appear to mitigate several of the negative consequences of Tat exposure, 
in vitro. (B) In vivo experiments further support in vitro data on the negative 
impact of drug use (e.g., ethanol) in the context of HIV-1 infection in patients on 
ART. Interestingly, a clinical report demonstrates a possible role for cannabinoids 
as an adjunctive therapy in HIV-1-infected patients on ART. 
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Figure 1.2. 
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inhibitors of Tat, which show promise in recent in vitro and in vivo studies, 
demonstrating an ability to inhibit Tat-dependent transcription (Mousseau et al., 
2012), as well as HIV-1 reactivation from latency (Mousseau et al., 2015; 
Kessing et al., 2017), with the ability to cross the BBB and prevent inflammation 
in the brains of Tat-transgenic mice (Mediouni et al., 2015). 
Drugs of abuse are their own confounding factor in neurological 
impairment and decline, and the prevalence of recreational drug use in the HIV-
1-infected population continues to present obstacles for greater clinical 
improvements in these patients (Nath et al., 2002; Green et al., 2004; Sharma 
and Ali, 2006; Theodore et al., 2007; Silverstein et al., 2011; Hauser et al., 2012; 
Nair and Samikkannu, 2012; Smith et al., 2014; Allain et al., 2015). Moreover, 
recreational drug and alcohol use in HIV-1-infected patients, as well as the use of 
prescription medications, over-the-counter drugs, and homeopathic regimens for 
comorbid conditions, present the potential for dangerous pharmacological 
interactions in this patient population (Stolbach et al., 2015). Given these 
observations, there is a need for more rigorous assessments of drug use in 
subsets of HIV-1-infected patient populations by performing more robust drug 
screenings and to question the current paradigm in order to truly appreciate the 
impact that single- and poly-drug use really has on HIV-1 infection in general 
(Parikh et al., 2012, 2014). This would also necessitate an understanding of the 
combined effects of alcohol and tobacco in combination with any of the drugs 
previously discussed, and will also increasingly need to include knowledge and 
understanding of cannabinoids in their various formulations as the growing 
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legalization of this drug and its use in pain management in the HIV-1-infected 
population is rising and will likely become more prevalently used in time. In 
addition, experimental and clinical Tat-mediated behavioral and molecular effects 
are exacerbated in the presence of a number of drugs of abuse, including 
opiates, cocaine, amphetamines, and ethanol (Figure 1.2.), underscoring the 
additional need for withdrawal interventions and counseling in a large percentage 
of HIV-1-infected patients. Nonetheless, the true impact of treatments used for 
these drugs [including withdrawal effects both acutely (prior to the next “hit”) and 
chronically (during long-term suppressive therapy or by complete elimination of 
the drug(s))] has not been well studied. Thus, withdrawal may have additional 
acute and chronic effects on HIV-1 infection and associated disease with one 
potential consequence being reactivation of virus from reservoirs. 
The development of ART has been critical in mitigating symptomatic 
decline and improving the overall clinical condition of those infected with HIV-1, 
as compared to the era before effective combination therapeutic control was 
available. However, the inability of current ART suppression to eliminate HIV-1 
reservoirs, including those in the CNS, underscores the need for additional 
research into alternative strategies. In this vein, recent in vitro findings utilizing 
gene-editing technology to target and excise integrated HIV-1 proviral genomes 
from latently infected cells exhibit exciting potential for the development of the 
next generation of antiretroviral therapy on the horizon (Hu et al., 2014; Kwarteng 
et al., 2017). Indeed, the benefits of ART are limited in the context of HAND 
progression in well-suppressed patients, and several reports emphasize the need 
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for improved therapeutic alternatives in the current era of the HIV-1 pandemic 
(Cysique et al., 2004; Robertson et al., 2007, 2010; Tozzi et al., 2007; Marra et 
al., 2009; Heaton et al., 2010, 2011; Simioni et al., 2010; Cysique and Brew, 
2011; Smurzynski et al., 2011). Thus, the advantages and disadvantages of ART 
with regard to neurocognitive impairment are currently under debate in the field 
and are yet to be fully determined. 
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2.1. Abstract 
Globally, the increasing incidence of injection drug use with opioids has 
been recognized, and is of particular concern in the HIV-1-infected population, 
where it is estimated that up to 30% of those infected actively consume opioids. 
Morphine (a product of heroin metabolism in humans) has been commonly 
prescribed to patients as a standard in pain management therapy for a variety of 
conditions, including neuropathy due to damage sustained in infections such as 
HIV-1. The mu opioid receptor (MOR-1) pathway is the most commonly 
characterized opioid receptor pathway in the morphine research literature. 
Morphine is also a known substrate of p-glycoprotein, an ATP-binding cassette 
efflux transporter expressed in multiple tissues, including the blood-brain barrier 
(BBB). The binding of morphine to either MOR-1 or p-glycoprotein may facilitate 
its entry into cells, allowing for access of morphine to enzymatic pathways which 
can generate morphine metabolites. In these studies, the hCMEC/D3 brain 
microvascular endothelial cell line was utilized to assess the ability of BBB 
endothelial cells to metabolize and transport morphine across an in vitro model. 
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2.2. Introduction 
The currently recognized opioid crisis/epidemic in the United States has 
been highlighted extensively in the media as of late. There is a continued rise in 
those reported to be addicted or misusing various opioids, including but not 
limited to heroin and morphine, and an ever-increasing number of cases of 
deaths by overdose. Globally, the increasing incidence of injection drug use with 
opioids such as heroin [which is metabolized into morphine in human livers and 
trafficked into various tissues throughout the body, including the CNS (De 
Gregori et al., 2012; Klimas and Mikus, 2014; Smith, 2009)] has been 
recognized, and is of particular concern in HIV-1-infected populations, where it is 
estimated that up to 30% of those infected actively consume opioids (Degenhardt 
and Hall, 2012). The social, legal, financial, and health-related detriments of the 
opioid crisis have been documented extensively, and debates have been on-
going on how to improve the current situation from the perspectives of health-
care and public-health interventions (Kolodny et al., 2015; Price, 2017; Seymour 
et al., 2017; Skolnick, 2017; Wen and Warren, 2017). Scientifically, the focus has 
been on attempting to elucidate the biochemical mechanisms involved in opioid 
analgesia and addiction, and how these can be translated into effective clinical 
intervention strategies for patients.  
 Morphine has been commonly prescribed to patients as a standard in pain 
management therapy for a variety of conditions, including neuropathy due to 
damage sustained in infections such as HIV-1, and is known to promiscuously 
bind and activate various receptors in humans, including but not limited to opioid 
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receptors and toll-like receptor 4 (TLR4). Of the four opioid receptors identified in 
the primary literature (i.e., delta, kappa, mu, and opioid-receptor-like1), the mu 
opioid receptor (MOR-1) pathway is the most commonly characterized opioid 
receptor pathway in the morphine research literature. Although morphine also 
binds and activates delta and kappa opioid receptors (Chu Sin Chung and 
Kieffer, 2013; Crowley and Kash, 2015), knock-out models suggest MOR-1 
activation by morphine mediates the majority of analgesia experienced in vivo 
(Kieffer and Gaveriaux-Ruff, 2002; Maldonado et al., 2017). Traditionally, MOR-1 
is described as a canonical G-protein coupled receptor (GPCR) in which binding 
of the receptor by an agonist initiates second-messenger cascades resulting in 
tissue-specific responses, including alterations to metabolism and cytoskeletal 
regulation; in addition to this, agonist binding can also result in phosphorylation of 
the receptor and recruitment of beta-arrestin and clathrin to the inner plasma 
membrane leaflet, resulting in endocytosis of the agonist:receptor complex 
(Stein, 2016; Violin et al., 2014; Zhang et al., 2015). Internalization of the GPCR 
complex is also believed to result in a physiological desensitization to further 
agonist input into the system until the receptor has been recycled back to the cell 
surface (Allouche et al., 2014; Roman-Vendrell et al., 2012; Stein, 2016; Violin et 
al., 2014; Zhang et al., 2015). In this way, morphine bound to MOR-1, which may 
be expressed by the blood-brain barrier (BBB), can potentially be internalized 
and metabolized by BBB cells. 
Morphine is also a known substrate of p-glycoprotein, an ATP-binding 
cassette efflux transporter expressed in multiple tissues, including the BBB, and 
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reported to be involved in the active transport of several other compounds 
(Dagenais et al., 2004; Hamabe et al., 2006; Kapur et al., 2014; Klimas and 
Mikus, 2014; Linnet and Ejsing, 2008; Sanchez-Covarrubias et al., 2014b; 
Seleman et al., 2014). Importantly, p-glycoprotein has been detected throughout 
various subcellular components of primary rat and human brain capillary 
endothelial cells in addition to expression along both the luminal and abluminal 
surfaces of the endothelium (Bendayan et al., 2006). This suggests that p-
glycoprotein may result in the entry of morphine and/or the active transport of 
morphine across the tissue, and thus may be involved in the overall pathway of 
morphine metabolism within BBB cells.  
Morphine metabolism is mediated biochemically by uridine-5’-diphosphate 
(UDP) glucuronosyltransferase (UGT) 2B7 (UGT2B7), which catalyzes 
glucuronidation of morphine resulting in the primary morphine metabolites, 
morphine-3-beta-D-glucuronide (M3G) and morphine-6-beta-D-glucuronide 
(M6G) (De Gregori et al., 2012; Klimas and Mikus, 2014; Smith, 2009). The 
metabolism of morphine in humans is compartmentalized by first-pass and 
second-pass pathways processed by UGT enzymes found primarily in the liver 
(first-pass metabolism), as well as in other organs and tissues throughout the 
body (second-pass metabolism), including the central nervous system (CNS) (De 
Gregori et al., 2012). However, while there are varying levels of support of the 
presence of UGT2B7 in the CNS, and it is hypothesized that endothelial cells of 
the BBB may be a sight of morphine metabolism, it has not previously been 
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demonstrated that BBB cells indeed produce conventional morphine metabolites 
(De Gregori et al., 2012; Ouzzine et al., 2014).   
The hCMEC/D3 human brain microvascular endothelial cell (BMEC) line 
has been extensively characterized in the literature for use as an acceptable in 
vitro blood-brain barrier model that has been utilized to investigate and describe 
various biochemical pathways of importance in the context of human disease 
pathologies (Hatherell et al., 2011; Sun et al., 2015; Weksler et al., 2013; 
Weksler et al., 2005). The use of hCMEC/D3 for the in vitro investigation of 
transport studies has been validated in the literature in in vitro transwell models, 
with the active transport (and inhibition of transport) of glucose (Al-Ahmad, 2017), 
methotrexate (Alam et al., 2017), tramadol (Kitamura et al., 2014), and cocaine 
(Chapy et al., 2014). In addition, the literature also supports utilization of 
hCMEC/D3 in the scrutiny of p-glycoprotein-mediated transport studies with gene 
expression of MDR1 (the p-glycoprotein gene) by mRNA quantitation, as well as 
protein expression of p-glycoprotein confirmed in the cell line (Dauchy et al., 
2009; Poller et al., 2008), although to a lesser extent as compared to primary 
human brain microvessel cell cultures (Dauchy et al., 2009). Furthermore, 
functional bi-directional transport of p-glycoprotein has also been shown in 
hCMEC/D3 (Dauchy et al., 2009; Poller et al., 2008), confirming their suitability 
for use in drug transport studies of the BBB. These cells may also express MOR-
1 and UGT2B7 (neither previously shown in the literature), and thus may process 
morphine via canonical GPCR and UGT pathways.   
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 2.3. Materials and Methods 
2.3.1. hCMEC/D3 media, hCMEC/D3 culture and in vitro blood-brain 
barrier generation 
Cells from the human brain microvascular endothelial cell line, hCMEC/D3 
(generously provided by Dr. Babette Weksler), were cultured in endothelial basal 
medium-2 (EBM-2; Lonza) supplemented with heat-inactivated fetal bovine 
serum (FBS; FBS Gold or Sigma; 5%), penicillin-streptomycin (Corning; 1%), 
hydrocortisone (Sigma-Aldrich; 1.4 uM), ascorbic acid (Sigma-Aldrich; 5 ug/mL), 
chemically defined lipid concentrate (Ceraplex; 1%), HEPES (Corning; 10 mM), 
and basic fibroblast growth factor (bFGF; Sigma-Aldrich; 1 ng/mL); referred to 
herein as complete hCMEC media. All experiments were performed between 
passages 27 to 32. Cells were grown on collagen-coated (Cultrex rat collagen I) 
60 cm2 Petri dishes (TPP), 6-well plates (Corning), or 3 m polycarbonate 3.8 
cm2 12-well transwell inserts (Corning). hCMEC/D3 cells were seeded at a 
density of 37,000 cells/cm2 in Petri dishes and 6-well plates and at 45,000 
cells/cm2 in 12-well transwell inserts, and grown to functional confluence prior to 
use in experimentation. 
2.3.2. Morphine and other drugs and reagents 
Morphine sulfate salt pentahydrate, naloxone hydrochloride dehydrate, 
zosuquidar hydrochloride, morphine-3-beta-D-glucuronide HPLC standard, 
morphine-6-beta-D-glucuronide HPLC standard, D-mannitol, and 70 kD FITC-
dextran were all obtained from Sigma-Aldrich. Antibodies for immunoblotting 
were obtained from Abcam (MOR-1 anti-human primary), Invitrogen (UGT2B7 
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anti-human primary), and Cell Signaling (beta-actin anti-human primary, HRP-
anti-mouse secondary, HRP-anti-rabbit secondary). Reagents for sample 
processing for UPLC-MS were obtained from Fisher Scientific (HPLC-grade 
methanol, HPLC-grade acetonitrile, HPLC-grade water), EMD Millipore (sodium 
hydroxide), and Fluka BioChemika (ammonium hydrogen carbonate). 
2.3.3. FITC-dextran permeability assay 
Monolayers of hCMEC/D3 cells grown to functional confluence on 3 M 
polycarbonate transwell inserts (6 days, as previously determined by FITC-
dextran permeability assays. Inserts were exposed to treatment conditions 
(detailed below), or for 30 minutes with 1.4 M mannitol (positive control for 
assay).  At time zero, all chambers were washed with warmed 10 mM HEPES in 
1X HBSS, followed by addition of unsupplemented EBM-2 media to bottom 
chambers and 2 mg/ml of 70 kD FITC-dextran (in unsupplemented EBM-2 
media) to top chambers. At 5-minute intervals up to 30 minutes, and at 60, 90, 
and 120 minutes, all bottom chambers were sampled, with a 100 l volume 
transferred to a white-walled optical-bottom 96-well plate. Fluorescence intensity 
was read on a Fluoroskan Ascent™ Microplate Fluorometer (Thermo Scientific) 
and utilized to calculate permeability coefficients for each treatment condition.  
2.3.4. Morphine exposure of hCMEC/D3 cultures, conditioned media 
collection, and whole cell lysate collection in methanol  
At confluence on 6-well plates or in 12-well transwell inserts, hCMEC/D3 
cells were exposed to 100 nM morphine (in complete hCMEC media) for up to 24 
hours. At precisely 1-hour intervals for 14 hours, and at 18-hour and 24-hour 
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time-points, conditioned media from the top and bottom chambers from exposed 
hCMEC/D3 wells (one well per time-point) were collected, flash-frozen on dry ice 
and stored at -20C. Cells were lysed by addition of HPLC-grade methanol 
directly to the cells (200 l to transwell inserts, 400 l to 6-wells), and these 
lysates were then incubated on ice for at least 30 minutes, collected, centrifuged 
to remove cell debris, and then supernatants were transferred to fresh tubes, 
flash-frozen and stored at -20C. 
2.3.5. Naloxone pre-treatment and zosquidar pre-treatment prior to 
morphine exposure of hCMEC/D3 cultures 
Pre-treatment of some hCMEC/D3 cultures was done prior to 
administration of 100 nM morphine. Naloxone pre-treatment was done for 2 
hours prior to morphine administration at concentrations of 200 nM or 400 nM 
naloxone in complete hCMEC media. Zosuquidar pre-treatment was done for 30 
minutes prior to morphine administration at concentrations of 500 nM or 1000 nM 
zosuquidar in complete hCMEC media. 
2.3.6. Whole cell lysate collection of hCMEC/D3 and immunoblotting 
for MOR-1 and UGT2B7 
hCMEC/D3 cultures were grown in 6 well plates to functional confluence 
(Strazza et al., 2016), washed twice with 1X HBSS, lysed with Pierce RIPA Lysis 
and Extraction Buffer (Thermo Scientific) supplemented with Halt Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific), scraped and collected into 
tubes, and then incubated for at least 30 minutes on ice with periodic agitation. 
Lysates were centrifuged, then supernatants were transferred to fresh tubes, 
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flash-frozen and stored at -20C. Lysates were concentrated by Amicon Ultra-0.5 
3K Centrifugal Filter Devices according to the manufacturer’s protocol (Millipore). 
Protein was then quantified by the Pierce BCA Protein Assay procedure, per the 
manufacturer’s protocol (Thermo Scientific). For immunoblotting, 10-30 ug of 
protein per sample was diluted with 2X Laemmli buffer and boiled for 5 minutes 
at 95-100C. Samples were then subjected to electrophorectic separation by 
SDS-PAGE, transferred onto PVDF membranes, probed and imaged via a 
standardized western blotting protocol. PVDF membranes containing samples 
were incubated with primary antibodies for 3 hours at 1:1000 (MOR-1), or at 
1:4000 (beta-actin), or at 1:500 (UGT2B7); after washing, they were then 
incubated with secondary antibodies for 2 hours at 1:4000 (HRP-anti-mouse or 
HRP-anti-rabbit). 
2.3.7. Preparation of LC-MS standards and morphine-exposure 
samples for UPLC-MS (Amicon 3K columns, solid phase 
extraction columns, etc.) 
Serial-diluted standards for morphine (stock concentration at 13.178 mM 
in deionized water), morphine metabolites (M3G and M6G; stock concentrations 
at 1.0 mg/ml in methanol), naloxone (stock concentration at 10 mM in deionized 
water), and zosuquidar (stock concentration at 9.48 mM) were made in complete 
hCMEC media and frozen and stored on the same days as experiments were 
conducted. All samples and standards were thawed on ice prior to preparation for 
UPLC-MS assay and analysis. Amicon Ultra-0.5 Centrifugal 3K Filter Devices 
were pre-washed once with 1 M NaOH and twice with MilliQ water according to 
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manufacturer’s protocol prior to use. Standards and samples were centrifuged 
through Amicon Ultra-0.5 Centrifugal 3K Filter Devices and the flow-through only 
was collected and processed through Oasis HLC 1CC vacuum cartridges 
(Waters) for solid phase extraction following a the manufacturer’s protocol. All 
were dried overnight in a speed vacuum apparatus and stored at room 
temperature in the dark prior to further processing. Immediately prior to UPLC-
MS, all samples and standards were reconstituted in 1 ml of HPLC-grade water, 
with 100 l of these contents assayed through the UPLC-MS. 
2.3.8. UPLC-MS conditions, chemicals used, flow rates, etc. 
Morphine and metabolites were analyzed on an Acquity I-Class UPLC 
system coupled to an Acquity TUV detector and Synapt G2Si HDMS mass 
spectrometer in positive ion mode with a heated electrospray ionization (ESI) 
source in a Z-spray configuration. LC separation was performed on a Waters 
Acquity UPLC BEH 1.7 m 2.1 x 50 mm column using an 0.6 ml/min isocratic 
solvent flow of A/B 95/5 for 4 minutes followed by washing and reconditioning the 
column. Eluent A is 0.1% formic acid in water and B is 0.1% formic acid in 
acetonitrile. Conditions on the mass spectrometer were as follows: capillary 
voltage 0.5 kV, sampling cone 40, source offset 80, source 120 C, desolvation 
250 C, cone gas 0, desolvation gas 1000 L/h, nebulizer 6.5 bar. Analyzer 
operated in resolution mode. Low energy collection between 100 and 1500 Da at 
0.2 sec scan time. MSe collected using a ramp trap collision energy 20-40V. 
Masses were extracted from the TOF MS TICs using an abs width of 0.05 Da. 
Naloxone (328.1541 m/z, retention time 1.54 min) was observed but zosuquidar 
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(calculated mass 527.61) could not be detected (Figure 2.1). Data was 
processed using Waters Masslynx and a pipeline using Waters Unifi was used 
for automated peak picking and integration. 
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Figure 2.1. UPLC-MS chromatograms (A) and mass spectra (B) of 125 nM 
standards of (bottom to top) morphine (286.1424), M6G (462.1711) and M3G 
(462.1711) metabolites.  
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Figure 2.1 
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2.3.9. Statistics 
Statistics were calculated utilizing GraphPad Prism version 6.0. Unpaired 
Student’s t-tests or ANOVA were performed to assess significance, as indicated.  
2.4. Results 
2.4.1. Morphine and metabolites do not appreciably degrade in 
culture media alone for 24 hours. 
Morphine’s clinical half-life in human plasma is reported to be 2 to 3 hours 
(Quinn et al., 1997), and in different in vitro cell culture systems has been 
reported to be between 2 to 7 hours (Gottas et al., 2016; Quinn et al., 1997), but 
this metric has not previously been reported for BBB cells in vitro. It is also 
known that the half-life of the primary morphine metabolites (M3G and M6G) 
ranges between 4 to 6 hours (Gottas et al., 2016). Thus, the stability of these 
compounds was tested under culture conditions in the absence of cells, in order 
to confirm their resistance to degradation in the absence of biochemical 
processing. 100 nM morphine, 100 ng/ml M3G, or 100 ng/ml M6G was incubated 
in complete hCMEC media in collagen-coated 6-well plates for a total of 24 
hours, with individual wells collected per time-point. Standard curves were 
generated for morphine, M3G, and M6G for extrapolation of values (Figure 2.2.A-
C). Appreciable degradation of either morphine or its metabolites was not 
observed over a 24 hour period under standard culture incubation conditions in 
the absence of cells (Figure 2.3.A-C). 
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Figure 2.2. UPLC-MS standard curves of morphine, M3G, and M6G. Fold 
dilutions of morphine sulfate, and HPLC-grade standards for M3G and M6G were 
prepared for the generation of standard curves. Standard curves of (A) morphine 
(0-1000 nM; peak at 0.45 minute), (B) M3G (0-500 ng/ml; peak at 0.27 minute), 
and (C) M6G (0-500 ng/ml; peak at 0.40 minute), were generated and utilized for 
extrapolation of concentration values from experimental time-points.  
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Figure 2.2 
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Figure 2.3. Morphine and metabolites do not appreciably degrade in culture 
media alone (no cells) for 24 hours. 100 nM morphine, 100 ng/ml M3G, or 100 
ng/ml M6G prepared in complete hCMEC media were incubated in collagen-
coated 6-well plates for up to 24 hours, and collected at indicated time-points for 
processing and analysis by UPLC-MS. UPLC-MS data demonstrates 
concentration values for (A) 100 nM morphine, (B) 100 ng/ml M3G, and (C) 100 
ng/ml M6G, over 24 hours.  
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Figure 2.3 
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2.4.2. hCMEC/D3 cultures express MOR-1 and UGT2B7, but do not 
produce morphine metabolites.  
Biologically, the conversion of morphine into its known primary 
metabolites, M3G and M6G, is catalyzed primarily in the human liver by 
UGT2B7, a member of the UDP glucuronosyltransferase enzyme family (De 
Gregori et al., 2012; Klimas and Mikus, 2014; Rowland et al., 2013; Smith, 2009). 
The presence of mRNA expression of UGT2B7 in human brain tissue (King et al., 
1999) and the ability of human brain homogenates to generate morphine 
metabolites in the presence of morphine (King et al., 1999; Yamada et al., 2003), 
have been previously reported, demonstrating the presence of active UGT2B7 in 
the human CNS; however, the role of the BBB itself, especially that of the 
BMECs, in morphine metabolism has not previously been addressed in the 
primary literature. In addition, the expression of the primary opioid receptors 
(notably mu, delta, and kappa opioid receptors) has not been previously 
demonstrated in hCMEC/D3 cells, or similar BMEC, in the primary literature. 
In order to test for the presence of active UGT2B7 in human BBB 
endothelial cells, hCMEC/D3 cultures (grown on collagen-coated 6-well plates or 
12-well transwell inserts) were exposed to a single-dose of 100 nM morphine, 
and conditioned media and whole cell lysates were collected throughout a 24 
hour period, processed, and then assayed by UPLC-MS for the presence of 
morphine, M3G, and M6G. In 6-well plates, there is no significant loss of 
morphine over a 24 hour period (Figure 2.4.A). In 12-well transwell chambers, 
there is a steady decline of morphine in the top chamber associated with an 
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increase in the bottom chamber (Figure 2.4.B). Interestingly, neither M3G nor 
M6G metabolites were observed in these experiments. 
In order to test for the expression of both MOR-1 and UGT2B7 in 
hCMEC/D3, cultures were exposed to either vehicle or 100 nM morphine for 24 
hours and whole cell lysates were collected and processed to assess protein 
expression by immunoblot. Protein expression of both MOR-1 and UGT2B7 were 
confirmed in hCMEC/D3 cultures (Figure 2.4.C). 
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Figure 2.4. hCMEC/D3 cultures express MOR-1 and UGT2B7, but do not 
produce morphine metabolites. hCMEC/D3 cultures were exposed to a single-
dose of 100 nM morphine for up to 24-hours; conditioned media and whole cell 
lysates were collected at the indicated time-points, then processed and assayed 
by UPLC-MS for the presence of morphine, M3G, and M6G. UPLC-MS data 
demonstrates concentration values from hCMEC/D3 cells exposed to morphine 
in replicate experiments in (A) 6-well plates or (B) 12-well transwell inserts. Bars 
graphed represent averages of nM values of morphine at each time-point +/- 
SEM. No M3G nor M6G peaks were observed in these experiments.  
(C) Representative immunoblots demonstrating protein expression of MOR-1 and 
UGT2B7 in hCMEC/D3 whole cell lysates after 24 hours of total exposure to 
vehicle or 100 nM morphine.  
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Figure 2.4 
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2.4.3. Pre-treatment with naloxone or zosuquidar does not prevent 
morphine entry into, or transport across, hCMEC/D3 cells.  
Given the transwell data observed in Figure 2.4.B, the functionality of 
MOR-1 and p-glycoprotein was examined in morphine entry and transport across 
BBB endothelial cells. The expression of p-glycoprotein in hCMED/D3 cells and 
its active function as a transporter of Rhodamine 123 has been previously 
documented in the literature (Dauchy et al., 2009; Poller et al., 2008); however, 
its role in the active transport of morphine in this in vitro BBB system has not 
been previously reported.  
A comparison of morphine concentration values of the apical and basal 
chambers over 24 hours indicates that in the absence of hCMEC/D3 cells, 100 
nM morphine added to the apical chambers quickly and freely disperses 
throughout the dual-chamber system. After 1 hour, about 50% of the morphine in 
the apical chamber moves to the basal chamber. After 6 hours, 80% of the 
morphine is lost from the apical chamber and moves to the basal chamber 
(Figure 2.5.A). In the presence of hCMEC/D3 cells, there is a steady decrease in 
morphine from the apical chambers paired to a concomitant increase of morphine 
seen in the basal chambers, reaching levels comparable to the no cells controls 
by hour 18 (Figure 2.5.A.). This delay in movement of morphine suggests a 
mechanism of regulated transport of morphine across hCMEC/D3 cells. Pre-
treatment with increasing concentrations of naloxone, a known MOR-1 inhibitor 
(Figure 2.5.B), or with increasing concentrations of zosuquidar, a p-glycoprotein-
specific inhibitor (Figure 2.5.C), did not prevent passage of morphine across 
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hCMEC/D3 transwells. The combined addition of the two inhibitors also did not 
prevent morphine transport across the in vitro BBB (Figure 2.5.D). In addition, 
pre-treatment with either inhibitor alone or in combination did not inhibit, nor 
significantly decreased, entry of morphine into hCMEC/D3 cells, as compared to 
morphine exposure in the absence of inhibitors (Table 2.1). In all cases, there is 
little morphine found in the cells (lysates) for any of the experimental paradigms 
(Table 2.1). 
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Figure 2.5. Pre-treatment with naloxone or zosuquidar does not prevent 
transport of morphine across hCMEC/D3 cells. (A) 100 nM morphine was 
added to the apical chambers of 3 M polycarbonate transwell inserts, with 
(closed bars) and without (open bars) hCMEC/D3 cells for up to 24 hours. (B-D) 
hCMEC/D3 cells cultured on 3 M polycarbonate transwell inserts were pre-
treated with naloxone (200 nM or 400 nM) for 2 hours (B), or with zosuquidar 
(500 nM or 1000 nM) for 30 minutes (C), or both (200 nM naloxone + 500 nM 
zosuquidar) (D), then exposed to a single-dose of 100 nM morphine for up to 24-
hours. Conditioned media from both chambers were collected at the indicated 
time-points, then processed and assayed by UPLC-MS for the presence of 
morphine, M3G, and M6G. UPLC-MS data graphed demonstrates averages of 
concentration values from conditioned media and lysates from hCMEC/D3 cells 
exposed in replicate experiments. Bars graphed represent averages of nM 
values of morphine at each time-point +/- SEM. No M3G nor M6G peaks were 
observed in these experiments.  
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Figure 2.5 
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Table 2.1. Pre-treatment with naloxone or zosuquidar neither inhibits nor 
significantly decreases entry of morphine in hCMEC/D3 cultures (lysates). 
hCMEC/D3 cells cultured on 3 uM polycarbonate transwell inserts were pre-
treated with naloxone (200 nM or 400 nM) for 2 hours, or with zosuquidar (500 
nM or 1000 nM) for 30 minutes, or both (200 nM naloxone +  500 nM 
zosuquidar), then exposed to a single-dose of 100 nM morphine for up to 24-
hours; conditioned media from both chambers and whole cell lysates were 
collected at the indicated time-points, then processed and assayed by UPLC-MS 
for the presence of morphine, M3G, and M6G. UPLC-MS data tabulated 
demonstrates averages of concentration values from whole cell lysates of 
hCMEC/D3 cells exposed in replicate experiments. Values represent averages of 
nM values of morphine at each time-point +/- SEM for replicate experiments. No 
M3G nor M6G peaks were observed in these experiments. 
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Table 2.1 
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2.4.4. 24-hour exposure of hCMEC/D3 cells to morphine, with and 
without pre-treatment with naloxone or zosuquidar, does not 
alter the basal rate of tracer molecule passage across 
hCMEC/D3 transwells.  
In order to determine if exposure to the various drugs was compromising 
the integrity of the hCMEC/D3 monolayer and thus inducing leakiness of the 
barrier beyond a normal baseline level, permeability of the in vitro BBB under the 
various treatment conditions was assessed by a FITC-dextran permeability 
assay. A 30-minute mannitol treatment on control wells prior to time zero for the 
exposure course served as a positive control for BBB compromise. Results from 
the permeability assay show that treatment with any combination of morphine, 
naloxone, or zosuquidar did not increase baseline leakiness of the monolayer, as 
compared to vehicle control, as there were no statistically significant differences 
noted in the permeability coefficients calculated for each group (Figure 2.6). 
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Figure 2.6. 24-hour exposure of hCMEC/D3 cells to morphine, with 
and without pre-treatment with naloxone or zosuquidar, does not 
alter the basal rate of tracer molecule passage across hCMEC/D3 
transwells. hCMEC/D3 cells cultured on 3 uM polycarbonate transwell 
inserts were either treated with vehicle, 100 nM morphine, 400 nM 
naloxone, 1000 nM zosuquidar, 200 nM naloxone + 500 nM zosuquidar, or 
200 nM naloxone + 500 nM zosuquidar + 100 nM morphine for 24 hours of 
total morphine exposure. Mannitol was incubated on control cells 30 
minutes prior to time-zero for the exposure course. Following exposure, all 
chambers were washed and permeability was assessed by determining 
the amount of 70 kDa FITC-dextran to pass from the upper to lower 
chamber over 120 minutes. Permeability coefficient (Pe) (A) and raw 
fluorescence intensity (RFI) (B) were calculated for the 30-minute and 
120-minute time-points. All courses were performed in triplicate and are 
representative of three independent experiments. Based on 95% 
confidence intervals no significant change was observed with any of the 
experimental exposure conditions. Mannitol treatment **** p<0.0001. 
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Figure 2.6 
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2.5. Discussion 
In the studies presented herein, the hCMEC/D3 BMEC line was utilized to 
assess the ability of BBB endothelial cells to metabolize and transport morphine 
across an in vitro BBB model. This cell line has been extensively characterized 
and validated against various other in vitro BBB models, including those 
comprised of primary BBB cells, in the literature (Eigenmann et al., 2013; 
Hatherell et al., 2011; Sun et al., 2015; Weksler et al., 2013; Weksler et al., 
2005). The cell line has also had prior validation for use in modeling drug 
transport studies of the BBB (Al-Ahmad, 2017; Alam et al., 2017; Chapy et al., 
2014; Kitamura et al., 2014), with confirmed expression and function of p-
glycoprotein (Dauchy et al., 2009; Poller et al., 2008), the lone implied transporter 
of morphine to date. In order to further justify utilizing these cells in a model of 
BBB exposure to morphine, the expression of MOR-1 (the most commonly 
recognized and described morphine receptor in the primary literature) and 
UGT2B7 (the singular morphine-metabolizing enzyme reported in the literature) 
were confirmed (Figure 2.4.C). 
Interestingly, while MOR-1 is primarily defined as a classical GPCR, it 
does not appear to function in this manner in hCMEC/D3 in the presence of 
morphine, as pre-treatment with increasing concentrations of naloxone (a 
clinically utilized opioid receptor antagonist) did not prevent or decrease entry of 
morphine into these cells (Table 2.1). Similar reports demonstrating a lack of 
morphine:MOR-1 internalization upon morphine exposure have been previously 
shown in studies conducted in the HEK293 human embryonic kidney cell line 
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(Keith et al von Zastrow 1996 and 1998), and in primary rat neurons in vivo 
(Keith et al von Zastrow 1998). 
In addition to this, while UGT2B7 expression of hCMEC/D3 was confirmed 
by immunoblot, as well as the observed internalization of morphine into the 
hCMEC/D3 cultures by UPLC-MS, no peaks for the primary morphine 
metabolites were observed throughout these studies in either conditioned media 
or whole cell lysates (Figures 2.4 and 2.5, and Table 2.1), indicating that the 
enzyme may not be functional in endothelial cells of the BBB, despite confirmed 
expression in this BMEC line. It is important to note that the UPLC-MS data was 
rigorously mined through for the potential presence of rarer metabolites that may 
have been generated in these experiments (such as normorphine, normorphine-
6-glucuronide, hydromorphone, or morphine-3,6-diglucuronide (Quinn et al., 
1997; Sartori et al., 2015; Smith, 2009)); however, no signatures of any potential 
metabolic derivatives of morphine were detected. Thus, while the catalytic activity 
of UGT2B7 in producing morphine metabolites in the human CNS has been 
demonstrated (King et al., 1999; Yamada et al., 2003), the current data suggests 
that the endothelial cells of the BBB are not actively involved in this metabolic 
process. It is also noted that primary rat microglia cultures are capable of 
generating the primary morphine metabolites, M3G and M6G (Togna et al., 
2013), suggesting that metabolism of morphine in the brain may be mediated by 
cells other than BMEC, with the role of BMEC limited to transport of morphine 
across from the peripheral circulation into the CNS. 
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The role of p-glycoprotein in the (unintentional) transport of morphine 
across the biologic BBB has been documented in both the clinical and bench 
science literature (Bartels and Meissner, 2017; De Gregori et al., 2012; Meissner 
et al., 2013; Sanchez-Covarrubias et al., 2014a; Sanchez-Covarrubias et al., 
2014b; Seleman et al., 2014), with its prevalent expression throughout the BBB 
endothelium demonstrated in primary human brain tissue (Bendayan et al., 
2006). Here, we sought to confirm the function of p-glycoprotein in the 
internalization and transport of morphine in the hCMEC/D3 BMEC line, which has 
been previously shown to express functional p-glycoprotein in the context of a 
transport assay utilizing Rhodamine 123 as the reporter substrate of p-
glycoprotein (Dauchy et al., 2009; Poller et al., 2008). The data herein 
demonstrate that pre-treatment with increasing concentrations of zosuquidar (a 
p-glycoprotein-specific inhibitor) did not prevent or decrease internalization of 
morphine into hCMEC/D3 cells (Table 2.1), nor did it prevent passage of 
morphine from the apical to the basal chambers of the in vitro transwell BBB 
model (Figure 2.5.C). This suggests that there may be additional transporters 
and receptors involved in the regulated internalization and transport of morphine 
across the BBB that have not yet been specified in the literature. The 
identification of such transporters and receptors, however, would be of clinical 
interest, particularly in the context of the pharmaceutical industry’s current push 
towards the development of non-addictive pain medications with strong analgesic 
properties, paired with an efficient and effective delivery into the CNS. 
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In vitro modeling of blood-brain barrier deregulation by morphine 
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3.1. Abstract  
The blood-brain barrier (BBB) functions in mediating cellular and 
molecular passage between the central nervous system (CNS) and the 
peripheral circulation. Compromise of the BBB has been linked to neurocognitive 
deficits sustained in multiple diseases and various infections, including HIV-1. 
Understanding the impact of exposure to pharmaceuticals (such as those utilized 
for pain management in CNS diseases) on BBB regulation and function is 
clinically important. Morphine, a mu-opioid and metabolic product of heroin 
breakdown in the body, is commonly prescribed for pain management for a 
variety of conditions, including neuropathy associated with damage caused by 
infections such as HIV-1. The mechanisms involved in regulation of immune cell 
transmigration across the BBB include reciprocal activation of brain 
microvascular endothelial cells (BMECs; the primary component cells of the BBB 
endothelium) and circulating leukocytes, resulting in coordinated expression of 
various molecular components, including but not limited to cell adhesion 
molecules (CAMs), tight junction proteins (TJPs), and chemokines. Previous 
studies demonstrate that exposure to morphine increases BBB permeability to 
cellular passage by modulating expression of CAMs. In these studies, the 
hCMEC/D3 BMEC line was utilized to demonstrate the role of morphine 
exposure in TJP regulation and chemokine gradients as underlying the molecular 
deregulation of an in vitro BBB model.  
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3.2. Introduction 
The blood-brain barrier (BBB) functions as a highly regulated and 
selective filter between the central nervous system (CNS) and the peripheral 
circulation, mediating cellular and molecular passage between these biologic 
compartments. The permeability of this barrier is regulated through the 
interconnected relationships of several biochemical pathways resulting in 
changes in the expression and activity of tight junction protein (TJP) complexes, 
adherens junction protein (AJP) complexes, cell adhesion molecules (CAM), 
specialized transport proteins, cytokines, receptors, and other molecules involved 
in the functional regulation of the endothelium. It is unsurprising, then, that BBB 
compromise has been associated with neurocognitive deficits sustained in 
multiple diseases, including stroke, multiple sclerosis, Alzheimer’s disease, 
Parkinson’s disease, and various infections, including HIV-1 (De Silva and 
Faraci, 2016; Desai et al., 2007; Krizanac-Bengez et al., 2004; Reinhold and 
Rittner, 2017; Salmina et al., 2010; Weiss et al., 2009). Thus, understanding the 
impact of exposure to pharmaceuticals (such as those utilized for pain 
management in such diseases) on BBB regulation and function is clinically vital. 
The primary cellular component of the BBB is brain microvascular endothelial 
cells (BMECs). The hCMEC/D3 human BMEC line exhibits morphological and 
functional characteristics comparable to primary human BMECs, including 
contact inhibition and stable expression of normal endothelial markers such as 
von Willebrand factor, CAMs, TJPs, AJPs, transporter proteins, and chemokine 
receptors (Bicker et al., 2014; Helms et al., 2016; Weksler et al., 2005), and has 
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been continuously validated in the literature for its use in the development of in 
vitro BBB models (Daniels et al., 2013; Eigenmann et al., 2013; Hatherell et al., 
2011; Huang et al., 2008; Jacob et al., 2015; Pu et al., 2005; Urich et al., 2012; 
Weksler et al., 2013). 
The mechanisms of regulating immune cell transmigration/diapedesis 
across endothelial tissues involve reciprocal activation of BMECs and circulating 
leukocytes, resulting in coordinated expression of various molecular components, 
including but not limited to CAMs, junctional complex proteins, and chemokines 
(Eugenin and Berman, 2003; Greenwood et al., 2011; Takeshita and Ransohoff, 
2012; Vestweber, 2012; Wu et al., 2000). The resultant transmigration of immune 
cells across the endothelium is believed to occur in one of two ways– para-
cellularly (in between endothelial cells; the predominant mode) or trans-cellularly 
(across endothelial cells; the less common mode)—although the literature 
suggests similar levels of participation of molecular factors, including dynamic 
expression patterns of junctional complex proteins, regardless of the mode of 
transmigration (reviewed in Williams et al., 2012). 
Morphine, a mu-opioid and metabolic derivative of heroin, is commonly 
prescribed for pain management for a variety of conditions, and has been directly 
linked with the ongoing crisis of opioid addiction and abuse present in the United 
States over the past several decades (Voon et al., 2017). The potentially 
unfavorable effects of morphine on the BBB (and how this may translate to CNS 
damage) have been demonstrated in in vitro studies which reported 
downregulation of mRNA expression of the tight junction proteins zona 
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occludens-1 and occludin, as well as enhanced secretion of the pro-inflammatory 
cytokines TNF- and IL-8 from primary human BMECs (hBMECs) exposed to 
morphine (Mahajan et al., 2008). Furthermore, morphine treatment of a co-
culture of primary human astrocytes with hBMECs resulted in an overall increase 
in permeability, including increased immune cell transmigration, across the in 
vitro BBB system (Mahajan et al., 2008). In addition to this, we have previously 
shown that prolonged morphine exposure (up to 72 hours) alters mRNA 
expression and increases protein expression of CAMs (namely, intercellular 
adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], and 
activated leukocyte cell adhesion molecule [ALCAM]) on hCMEC/D3 cultures, 
and also enhanced firm adhesion of primary human PBMCs to the hCMEC/D3 
monolayer (Strazza et al., 2016).  
These previous studies suggest that exposure to mu-opioids such as 
morphine increases BBB permeability to cellular passage by modulating 
expression of TJPs and CAMs. However, the role of morphine in the generation 
of chemotactic gradients, such as those of MCP-1 and SDF-1, both of which 
have confirmed roles in the chemotaxis of monocytes and lymphocytes in vivo 
and in vitro (Arenzana-Seisdedos, 2015; Deshmane et al., 2009; Eugenin et al., 
2006; Mahad et al., 2006; Man et al., 2012; Weiss et al., 1998; Wu et al., 2000), 
has not previously been addressed. 
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3.3. Materials and Methods 
3.3.1. hCMEC/D3 media, hCMEC/D3 culture and in vitro blood-brain 
barrier generation 
Cells from the human brain microvascular endothelial cell line, hCMEC/D3 
(generously provided by Dr. Babette Weksler), were cultured in endothelial basal 
medium-2 (EBM-2; Lonza) supplemented with heat-inactivated fetal bovine 
serum (FBS; FBS Gold or Sigma; 5%), penicillin-streptomycin (Corning; 1%), 
hydrocortisone (Sigma-Aldrich; 1.4 uM), ascorbic acid (Sigma-Aldrich; 5 ug/mL), 
chemically defined lipid concentrate (Ceraplex; 1%), HEPES (Corning; 10 mM), 
and basic fibroblast growth factor (bFGF; Sigma-Aldrich; 1 ng/mL); referred to 
herein as complete hCMEC media. All experiments were performed between 
passages 27 to 32. Cells were grown on collagen-coated (Cultrex rat collagen I) 
60 cm2 Petri dishes (TPP), 6-well plates (Corning), or 3 um polycarbonate 3.8 
cm2 12-well transwell inserts (Corning). hCMEC/D3 cells were seeded at a 
density of 37,000 cells/cm2 in Petri dishes and 6-well plates, and at 45,000 
cells/cm2 in 12-well transwell inserts, and grown to functional confluence prior to 
use in experimentation. 
3.3.2. Morphine, naloxone, and other reagents 
Morphine sulfate salt pentahydrate, naloxone hydrochloride dehydrate, D-
mannitol, and 70 kD FITC-dextran were all obtained from Sigma-Aldrich. Flow 
cytometry antibodies were obtained from Abcam (MOR-1 anti-human primary) 
and Cell Signaling (HRP-anti-rabbit secondary). Primers for qPCR were obtained 
from ABI Systems. 
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3.3.3. FITC-dextran permeability assay 
Monolayers of hCMEC/D3 cells were grown to functional confluence on 
collagen-coated 3 M polycarbonate transwell inserts by 6 days, as previously 
determined by FITC-dextran permeability assays. Inserts were exposed to 
treatment conditions (detailed below), or for 30 minutes with 1.4 M mannitol 
(positive control for assay). At time zero, all chambers were washed with warmed 
10 mM HEPES in 1X HBSS, followed by addition of unsupplemented EBM-2 
media to bottom chambers and 2 mg/ml of 70 kD FITC-dextran (in 
unsupplemented EBM-2 media) to top chambers. At 5-minute intervals up to 30 
minutes, and at 60, 90, and 120 minutes, all bottom chambers were sampled, 
with a 100 l volume transferred to a white-walled optical-bottom 96-well plate. 
Fluorescence intensity was read on a Fluoroskan Ascent™ Microplate 
Fluorometer (Thermo Scientific). The six time points at 5 minute intervals were 
utilized to calculate permeability coefficients (Pe), or rate of passage through the 
monolayer, for each treatment condition.   
Pe = PS/s, where PS (clearance) is the permeability surface area of the 
endothelial monolayer and s is the surface area of the filter (1.12 cm2). PS is 
given by 1/PS = 1/me – 1/mf, where me and mf are the slopes of the curves 
corresponding to endothelial cells on filters and to filters only, respectively, with 
me and mf calculated by plotting the cleared volume against time. The cleared 
volume was calculated by (AUa – AUb)/Fi, where AUa is the total fluorescence 
(arbitrary units) in the basal compartment, AUb is the background fluorescence 
and Fi is the fluorescence of the initial solution (AU/ml). 
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3.3.4. Morphine exposure of hCMEC/D3 cultures and collection of 
RNA and conditioned media 
At confluence on 12-well transwell inserts, hCMEC/D3 cells were exposed 
to vehicle, 100 nM or 200 nM morphine (in complete hCMEC media) for up to 72 
hours, with or without re-administration (“no spikes” or “spikes”). At time-zero, 
conditioned media from the apical and basal chambers of exposed transwells 
were harvested, flash-frozen and stored until utilized to assess cytokine 
expression profiles by ELISA (detailed below).  
Monolayers of hCMEC/D3 cells grown to functional confluence on 6-well 
plates were exposed to vehicle or 100 nM morphine (in complete hCMEC media) 
for up to 72 hours, with or without re-administration (“no spikes” or “spikes”) at 
the indicated time-points. At time-zero, lysates containing total RNA were 
collected by addition of Qiazol to cultures, and RNA was extracted utilizing the 
RNeasy Plus Mini Kit procedure (Qiagen), per the manufacturer’s protocol.  
3.3.5 Tight junction protein RT qPCR 
RNA from experimental cultures was extracted utilizing the RNeasy Plus 
Mini Kit procedure (Qiagen), per the manufacturer’s protocol. Reverse 
transcription of RNA for generation of cDNA was performed utilizing the 
SuperScript III First Strand Synthesis Kit procedure (Invitrogen/Life 
Technologies), per the manufacturer’s protocol. qPCR was performed on cDNA 
utilizing Taqman Gene Expression primer-probe sets for human occludin, zona 
occludens-1, claudin-1, claudin-5, and GAPDH (Applied Biosystems), along with 
Taqman Universal PCR Master Mix (Applied Biosystems). Quantitative analyses 
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of mRNA were conducted using an Applied Biosystems 7300 Real-Time PCR 
System (Applied Biosystems, CA). Data were normalized using Ct values for 
GAPDH and β-actin in each sample. Relative levels of mRNA expression were 
calculated as log2 relative units using the geometric mean of the average Ct 
values for GAPDH and β-actin, and fold change was calculated for each 
treatment compared to untreated. 
3.3.6 Flow cytometry of hCMEC/D3 cultures for MOR-1 
Monolayers of hCMEC/D3 cells grown to functional confluence on 6-well 
plates were exposed to vehicle or morphine at the indicated concentrations, 
incubation periods, and re-administration conditions. At time-zero, cells were 
harvested and subjected to a standardized surface staining protocol for flow 
cytometric analysis. Sample data were collected on a BD LSRFortessa and 
analyzed on FlowJo software. 
3.3.7. MCP-1 and SDF-1 ELISAs 
Monolayers of hCMEC/D3 cells grown to functional confluence on 
collagen-coated 3 uM polycarbonate transwell inserts were exposed to vehicle, 
morphine, or naloxone at the indicated concentrations, incubation periods, and 
re-administration conditions. At time-zero, conditioned media from the apical and 
basal transwell chambers were collected and assayed by ELISA for cytokine 
analysis. Standardized kits for MCP-1 (eBioscience) and SDF-1 (R & D Systems) 
were utilized to determine cytokine concentrations of transwell chambers, 
following manufacturers’ protocols. 
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3.3.8. Naloxone pre-treatment prior to morphine exposure of 
hCMEC/D3 cultures 
Pre-treatment of some hCMEC/D3 cultures with 200 nM or 400 nM 
naloxone in complete hCMEC media for 2 hours was performed prior to 
administration of morphine. 
3.3.9. Statistics 
Statistics were calculated utilizing Microsoft Excel and GraphPad Prism 
version 6.0. Unpaired Student’s t-tests or ANOVA were performed to assess 
significance. 
3.4. Results 
3.4.1. Morphine exposure does not alter the basal rate of tracer 
molecule passage across hCMEC/D3 BBB cells, regardless of 
single or repeated administration of morphine. 
Clinical concentrations of morphine in patients undergoing daily pain-
therapy regimens, including those for cancers, have been reported to range from 
40 nM to over 1000 nM in the blood, and from 1 nM up to 200 nM in the 
cerebrospinal fluid (CSF) (reviewed in Klimas and Mikus, 2014), thus the studies 
herein utilize morphine concentrations of 100 nM and 200 nM to reflect in vivo 
clinical concentrations of morphine observed upon daily exposure to this drug. 
Previous studies also report differential outcomes of morphine exposure on BBB 
permeability to tracer molecule passage, depending on whether the system is in 
a state of constant, repeated exposure versus withdrawal post-morphine 
exposure (Sharma and Ali, 2006; Strazza et al., 2016; Yousif et al., 2008). Here, 
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we assessed whether single or repeated administrations of morphine over 24, 
48, or 72 hours alters tracer molecule passage across the hCMEC/D3 in vitro 
BBB by a FITC-dextran permeability assay. A 30-minute mannitol treatment on 
control wells prior to time-zero for the exposure course served as a positive 
control for BBB compromise. Results from the permeability assay show that 
treatment with increasing biologic concentrations of morphine (100 nM and 200 
nM), whether under single administration (“no spikes”) or repeated administration 
(“spikes”) conditions, did not increase baseline leakiness of the monolayer over 
24, 48, or 72 hours, as compared to vehicle controls (Figure 3.1.A-L). 
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Figure 3.1. Morphine exposure does not alter the basal rate of tracer 
molecule passage across hCMEC/D3 BBB cells, regardless of single or 
repeated administration of morphine. hCMEC/D3 cells cultured on collagen-
coated 3 M polycarbonate transwell inserts were either treated with vehicle, 100 
nM morphine (A, B, E, F, I, J), or 200 nM morphine (C, D, G, H, K, L), for a total 
of 24 (A-D), 48 (E-H), or 72 hours (I-L). Re-administration of vehicle or morphine 
(“spikes”) were done every 24 hours, with final re-administration done at 2 hours 
before time-zero, for all end-points. Mannitol was incubated on control cells 30 
minutes prior to time-zero for each exposure course. Following exposure, all 
chambers were washed and permeability was assessed by determining the 
amount of 70 kDa FITC-dextran to pass from the upper to lower chambers over 
120 minutes. Permeability coefficient (Pe) and raw fluorescence intensity (RFI) 
were calculated. All courses were performed in triplicate and are representative 
of three independent experiments. Based on 95% confidence intervals no 
significant change was observed with any of the experimental exposure 
conditions. Mannitol treatment *** p<0.0001. 
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Figure 3.1. 
 
 
 
104 
 
 
 
 
  
105 
 
3.4.2. Chronic morphine exposure decreases tight junction protein 
mRNA expression in hCMEC/D3 BBB cells. 
The importance of tight junction proteins in homeostatic maintenance of 
mammalian biology, including the BBB vasculature and CNS health, is 
highlighted by in vivo studies demonstrating delayed development and eventual 
lethality of zona occludens-1 knock-out murine embryos by E11 (Katsuno et al., 
2008), as well as post-natal lethality of both claudin-1 (Furuse et al., 2002) and 
claudin-5 (Nitta et al., 2003) knock-out murine infants within one day of 
parturition. Claudin-5 knock-out embryos also demonstrated overt increased 
permeability of the BBB to small tracer molecule passage in vivo, as compared 
with wild-type littermates (Nitta et al., 2003). In cases of wild-type or normal 
baseline expression of TJPs, disruption of the BBB by downregulated expression 
of these proteins has been linked to various disease pathologies, including those 
related to increased immune cell infiltration into the CNS (Almutairi et al., 2016; 
Dallasta et al., 1999; Eugenin et al., 2006; Greenwood et al., 2011; Persidsky et 
al., 2006; Reinhold and Rittner, 2017; Vestweber, 2012).  
In order to assess the effects of morphine exposure to mRNA expression 
of TJPs of hCMEC/D3 cultures, cultures exposed to either vehicle or 100 nM 
morphine (after single and repeated administrations of morphine for up to 72 
hours) were harvested and assayed for mRNA expression of occludin, zona 
occludens-1, claudin-1, and claudin-5 by RT qPCR. Results from mRNA analysis 
showed that cultures subjected to only single administrations of morphine over 
24, 48, or 72 hours did not exhibit alterations in mRNA expression of the TJPs 
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assayed for (data not shown); however, repeated administrations of morphine 
over a prolonged exposure course (72 hours) resulted in downregulation of TJP 
mRNA in hCMEC/D3 cells, as compared to vehicle exposures (Figure 3.2.A-D). 
 
  
107 
 
Figure 3.2. Chronic morphine exposure decreases tight junction protein 
mRNA expression in hCMEC/D3 BBB cells. hCMEC/D3 cells cultured on 
collagen-coated 6-well plates were exposed to either vehicle or 100 nM morphine 
for a total of 24, 48, or 72 hours. Re-administrations of vehicle or morphine were 
done every 24 hours, with final re-administrations done at the indicated time-
points before time-zero, for all end-points. Following exposure, whole cell lysates 
were harvested, processed, and assayed for mRNA expression of tight junction 
proteins by RT qPCR. Graphed are expression levels for Occludin (A), Zona 
Occludens-1 (B), Claudin-1 (C), and Claudin-5 (D).  All bars represent the 
average percentages of relative mRNA expression compared to vehicle, with 
vehicle normalized to 100%. Relative mRNA is calculated based on GAPDH 
expression. Each bar is the average of 4 independent treatments +/- SEM.  
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Figure 3.2. 
 
 
 
  
A. B.
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3.4.3. Prolonged morphine exposure alters MOR-1 surface 
expression on hCMEC/D3 cells. 
The mu-opioid receptor MOR-1 is considered the primary opioid receptor 
bound by morphine in vivo. The accepted paradigm for the canonical 
morphine:MOR-1 G-protein coupled receptor (GPCR) pathway states that 
morphine binding of MOR-1 causes endocytosis of the receptor:agonist complex 
resulting in decreased expression of MOR-1 at the cell surface of morphine-
exposed cells. In order to test for surface expression of MOR-1 on hCMEC/D3 
after single and repeated administrations of morphine, we harvested cultures 
exposed to either vehicle or morphine for up to 72 hours, then stained and 
assayed them for MOR-1 surface expression by flow cytometry. Results from the 
flow cytometric analysis show that hCMEC/D3 cells indeed express MOR-1 on 
their surface, as compared to unstained and secondary antibody controls (Figure 
3.3.A), and that the mean fluorescence intensity (MFI) of MOR-1 surface 
expression does not change appreciably after a short-term 24-hour exposure of 
morphine, regardless of concentration or single versus repeated administrations 
(Figure 3.3.B). The data also indicate, however, that a prolonged exposure to 
morphine alters the MFI of MOR-1 surface expression, with a statistical decrease 
observed with a single administration and increases in MOR-1 observed with 
repeated administrations over 72 hours (Figure 3.3.C). 
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Figure 3.3. Prolonged morphine exposure alters MOR-1 surface expression 
on hCMEC/D3 cells. hCMEC/D3 cells cultured on collagen-coated 6-well plates 
were exposed to either vehicle or 100 nM or 200 nM morphine in complete 
hCMEC media for a total of 24 or 72 hours. Re-administration of vehicle or 
morphine (“spikes”) were done every 24 hours, with final re-administrations done 
at 2 hours before time-zero, for all end-points. Following exposure, cells were 
harvested, processed, and assayed for MOR-1 protein surface expression by 
flow cytometry. Graphed are the mean fluorescence intensity (MFI) expression 
levels of MOR-1 on annexin V-negative hCMEC/D3. All courses were performed 
in triplicate.  
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Figure 3.3.  
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3.4.4. Repeated, prolonged morphine exposure induces cytokine 
gradients across the in vitro human BBB model.  
In order to address the potential role of morphine exposure in the 
generation of chemotactic gradients by the BBB, hCMEC/D3 monolayers 
nM or 200 nM morphine for up to 72 hours, with either single or repeated 
administrations of vehicle or morphine every 24 hours. Conditioned media from 
the apical and basal chambers were assayed for cytokine expression of MCP-1 
(CCL2) and SDF-1 (CXCL12) by ELISA. MCP-1 and SDF-1 were assayed for 
because of their recognized roles in the chemotaxis of monocytes and 
lymphocytes in vivo and in vitro (Arenzana-Seisdedos, 2015; Deshmane et al., 
2009; Eugenin et al., 2006; Mahad et al., 2006; Man et al., 2012; Weiss et al., 
1998; Wu et al., 2000). Our results demonstrate that repeated administrations of 
morphine at either concentration over longer exposure courses (48 and 72 hours) 
decreases apical chamber concentrations of MCP-1 (Figure 3.4.C and E) 
resulting in the generation of chemotactic gradients (Figure 3.4.D and F). 
Interestingly, basal chamber concentrations of SDF-1 were increased after 
repeated morphine administrations at only the 100 nM morphine exposures 
across all end-points (Figure 3.4.G, I, and K), also resulting in the generation of 
chemotactic gradients (Figure 3.4.H, J, and L).  
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Figure 3.4. Repeated, prolonged morphine exposure induces cytokine 
gradients across the in vitro human BBB model. Following exposure of 
hCMEC/D3 monolayers on collagen-coated 3 M polycarbonate transwells with 
vehicle, 100 nM, or 200 nM morphine in complete hCMEC media for 24 (A, B, G, 
H), 48 (C, D, I, J), or 72 hours (E, F, K, L), with either single or repeated 
administrations every 24 hours with the final re-administrations done at 2 hours 
before time-zero, for all end-points. Conditioned media from apical and basal 
chambers were harvested and assayed for cytokine expression profiles by 
ELISA. MCP-1 (A-F) and SDF-1 (G-L) protein levels were measured and 
analyzed. Graphed are raw pg/ml values (A, C, E, G, I, K) and fold-change of 
pg/ml values from chambers within each treatment condition (B, D, F, H, J, L). 
Bars represent triplicates of individual experiments +/- SD. *p≤0.01, **p≤0.001, 
***p≤0.0001, ****p≤0.00001, as determined by student’s t-test. 
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Figure 3.4. 
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3.4.5. Pre-treatment with naloxone abrogates morphine-induced 
cytokine gradients across hCMEC/D3 chambers. 
In order to determine if the chemokine gradients being generated by 
morphine exposure of hCMEC/D3 BBB cells (Figure 3.4) are potentially being 
mediated by a morphine:MOR-1 agonist relationship, hCMEC/D3 transwells  
were pre-treated with 200 nM naloxone, a known MOR-1 inhibitor, prior to 
exposure to 100 nM morphine. The data demonstrate that repeated naloxone 
exposure alone does not itself alter MCP-1 expression as compared to vehicle 
control. However, naloxone-plus-morphine exposure abrogates the MCP-1 
gradient generated by repeated morphine exposure alone, over 72 hours (Figure 
3.5). 
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Figure 3.5. Pre-treatment with naloxone abrogates morphine-induced 
cytokine gradients across hCMEC/D3 chambers. hCMEC/D3 cells cultured on 
collagen-coated 3 M polycarbonate transwell inserts were either exposed to 
vehicle (pink) or 100 nM morphine (red), with repeated administrations as done 
for Figure 3.4., or pre-treated with 200 nM naloxone in complete hCMEC media 
for 2 hours, then exposed to vehicle (gray) or 100 nM morphine (black), with 
repeated administrations every 24 hours as done for Figure 3.4., up to 72 hours. 
Conditioned media from apical and basal chambers were harvested and assayed 
for MCP-1 expression by ELISA. Graphed are raw pg/ml values (A) and fold-
change of pg/ml values from chambers within each treatment condition (B). Bars 
represent triplicates of individual experiments +/- SD. ***p≤0.001, ****p≤0.0001 
as determined by student’s t-test.  
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Figure 3.5. 
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3.5. Discussion 
In the studies presented herein, the hCMEC/D3 BMEC line was utilized to 
generate an in vitro BBB model in order to assess the biochemical effects of 
morphine exposure on BBB endothelial cells. Exposure of hCMEC/D3 to 
increasing biologic concentrations of morphine up to 72 hours did not overtly 
increase baseline leakiness of the monolayer to small molecule passage, 
regardless of single versus repeated administrations (Figure 3.1.), despite 
observed downregulation of TJP mRNA after repeated administrations of 
morphine over 72 hours (Figure 3.2.), as compared to vehicle controls. 
 We previously demonstrated a lack of conventional morphine:MOR-1 
GPCR behavior in hCMEC/D3 up to 24 hours after a single administration of 
morphine (Chapter 2), which is further supported by flow cytometry data 
demonstrating a lack of change in MFI of MOR-1 surface expression after 24 
hours of morphine, regardless of concentration used or single versus repeated 
administration (Figure 3.3.B.). Interestingly, further non-canonical 
morphine:MOR-1 behavior was observed after prolonged exposure to morphine 
for 72 hours of repeated morphine exposures with statistically significant 
increases in MOR-1 surface expression measured (Figure 3.3.C.). 
HIV-1 associated neurocognitive disorders (HAND) manifests in up to 69% 
of infected patients (Simioni et al., 2010). It has been reported that levels of 
MCP-1 protein are increased in the brains and cerebral spinal fluid (CSF) of 
patients diagnosed with HIV-1 associated dementia (HAD) (Conant et al., 1998), 
as well as in the brains of those diagnosed with HIV-1 encephalitis (HIVE) 
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(McManus et al., 2000). Interestingly, in vitro models have demonstrated the 
influence of morphine (Mahajan et al., 2008) as well as of exogenous MCP-1 
input (Eugenin et al., 2006) on the enhanced transmigration of primary human 
PBMCs (artificially infected with different strains of HIV-1) across in vitro BBB  
models comprised of primary human astrocyte-endothelial cell co-cultures, 
supporting the “Trojan Horse” theory of HIV-1-infected immune cells (i.e. 
monocytes and CD4+ T cells) traversing the BBB and thus introducing the virus 
into the CNS (Fischer-Smith and Rappaport, 2005). It is believed that this 
seeding of virus into the CNS and the resultant pro-inflammatory state and 
neuronal damage are the major contributors to the clinical presentations of 
HAND in patients. Support for the influence of SDF-1 in this process is provided 
by clinical reports which demonstrate increased levels of SDF-1 in the primary 
brain tissue of HAD patients (Rostasy et al., 2003), as well as in vitro studies 
which demonstrate significant transmigration of various primary human immune 
cells, including monocytes and CD4+ T cells, in response to an exogenous input 
of SDF-1 into an in vitro BBB system comprised of the THBMEC line (Man et al., 
2012). Consideration of these reports led to examining the possible role of the 
commonly prescribed mu-opioid morphine in contributing to HIV-1 CNS disease. 
Repeated administrations of morphine resulted in the generation of chemotactic 
gradients of both MCP-1 and SDF-1 across the in vitro BBB, over both shorter 
and longer exposure courses (Figure 3.4), a finding not previously reported in the 
literature. This suggests that clinical doses of morphine may be exacerbating 
some aspects of HIV-1 CNS disease pathologies by contributing to an increased 
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transmigration of HIV-1-infected immune cells into the brains of patients taking 
morphine, as well as those who consume heroin or morphine in an addiction 
scenario. Interestingly, pre-treatment with naloxone, a known MOR-1 antagonist, 
abrogated morphine’s effects on BBB chemokine gradient generation (Figure 
3.5), implying that these effects on the BBB may be mediated in a 
morphine:MOR-1 manner, however, our previous data suggests this may be 
occurring in a non-canonical-GPCR manner.   
An alternative rationalization for the morphine effects observed in our 
model stems from accumulating evidence in the literature which supports a role 
for morphine as a toll-like receptor (TLR)- 4 (TLR4) agonist. It has been reported 
that primary human and rat BMEC indeed express relevant TLRs, including 
TLR2, TLR3, TLR4, AND TLR6 (Nagyoszi et al., 2010), and that there are direct 
relationships between TLR4 activation and expression of MCP-1 (Ishikado et al., 
2009; Kang et al., 2009; Pirvulescu et al., 2014; Zeuke et al., 2002) and SDF-1 
(Dutta and Roy, 2015; Yang et al., 2015) in a variety of cells types and systems, 
in vitro and in vivo. It has also been shown that naloxone, a popular MOR-1 
antagonist that is clinically prescribed, also inhibits TLR4 activation in vivo (Chin 
et al., 2016; Lewis et al., 2012) and in vitro (Wang et al., 2016). Therefore, it is 
probable that our observations have been mediated by a morphine:TLR4 
interaction, as opposed to a morphine:MOR-1 interaction, despite our 
confirmation of expression of MOR-1 in hCMEC/D3 by western blot (Chapter 2) 
and flow cytometry (Figure 3.3). These studies will be interesting to explore in the 
future. 
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4.1. Abstract  
The clinical consequences of HIV-1 infection of the central nervous 
system (CNS) can manifest as a spectrum of HIV-1-associated neurocognitive 
disorders (HAND), ranging from a mild neurocognitive impairment (NCI) to more 
severe forms, including HIV-1-encephalitis (HIVE) and HIV-1-associated 
dementia (HAD). Tat (an HIV-1 protein highlighted in the literature for its role in 
BBB deregulation and disruption) functions as a transcriptional regulator of both 
viral and host genes, and is continuously produced and released by HIV-1-
infected cells throughout the course of infection in patients, regardless of 
successful treatment with anti-retroviral therapy (ART). The blood-brain barrier 
(BBB) is comprised primarily of brain microvascular endothelial cells (BMECs) 
and forms a functional, dynamic, semi-permeable barrier designed to protect the 
brain and maintain CNS homeostasis through regulated communication with the 
periphery. Several reports in the primary literature highlight Tat’s negative impact 
on various CNS cells (including those of the BBB) and have demonstrated Tat’s 
role in altering BBB permeability in various ways, including deregulated 
expression of TJP, CAM, and cytokines, resulting in enhanced immune migration 
across various BBB models. In these studies, the hCMEC/D3 BMEC line was 
utilized to test the role of recombinant Tat exposure in the generation of 
chemokine gradients across an in vitro BBB model. Several concentrations of 
“naked” Tat or Tat packaged in liposomes were tested. Neither had an effect on 
MCP-1 or SDF-1 chemokine gradients. This suggests that while Tat has several 
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roles in deregulation of the barrier, inducing altered chemokine gradients may not 
be one of them. 
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4.2. Introduction 
Confirmation that human immunodeficiency virus-1 (HIV-1) seeds viral 
reservoirs early in the clinical course, with a potential for latency and reactivation 
of these reservoirs, has been made in recent years by reports of viral rebounds 
after discontinued anti-retroviral therapy (ART) in patients, including the 
VISCONTI cohort in France (Saez-Cirion et al., 2013), and both the so-called 
“Boston patients” (Henrich et al., 2013) and the “Mississippi baby” patient 
(Luzuriaga et al., 2015; Persaud et al., 2013) in the United States. It is theorized 
that this initial viral seeding includes a breach of the blood-brain barrier (BBB) by 
HIV-1, establishing a central nervous system (CNS) reservoir within hours or 
days after infection (Fois and Brew, 2015; Gray et al., 2014; Joseph et al., 2015). 
The clinical consequences of this CNS infection can then manifest as a spectrum 
of HIV-1-associated neurocognitive disorders (HAND), ranging from a mild 
neurocognitive impairment (NCI) to more severe forms, including HIV-1-
encephalitis (HIVE) and HIV-1-associated dementia (HAD) (Kovalevich and 
Langford, 2012; McArthur et al., 2010; Toborek et al., 2005). The mechanisms 
proposed for how the virus enters the CNS include a “Trojan Horse” model 
whereby HIV-1-infected immune cells (i.e. monocytes and CD4+ T cells) traverse 
the BBB, as well as cell-free virus directly crossing the barrier (Fischer-Smith and 
Rappaport, 2005).  
Various viral proteins released from infected cells during the course of 
infection appear to actively mediate a continuous CNS assault, resulting in long-
term chronic inflammation and tissue damage, which is at least partially attributed 
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to a majority of patients experiencing some extent of HAND (with some estimates 
as high as 69% in well-controlled patients; (Simioni et al., 2010)), including a 
progression to HAD in a percentage of cases despite treatment with ART 
(Cysique and Brew, 2011; Cysique et al., 2004; Heaton et al., 2010; Heaton et 
al., 2015; Heaton et al., 2011; Robertson et al., 2007; Robertson et al., 2010; 
Tozzi et al., 2007). The viral proteins primarily highlighted in the literature for their 
roles in BBB deregulation and disruption are Tat, Env, Nef, and Vpr.   
The transactivator of transcription (Tat) of HIV-1 functions as a 
transcriptional regulator of both viral and host genes. It is known to interact 
directly with the viral TAR element, as well as the host RNA polymerase II, 
mediating viral replication (Frankel and Young, 1998; Friedrich et al., 2011; 
Ramakrishnan et al., 2012). Tat is also reported to deregulate the expression and 
activity of several host factors involved in various aspects of cellular and 
organismal homeostasis, including metabolism, inflammatory regulation, and 
apoptosis (Debaisieux et al., 2012; Jeang et al., 1999; Li et al., 2012b). Clinically, 
Tat is continuously produced and released by HIV-1-infected cells throughout the 
course of infection, and is detected in the cerebrospianal fluid (CSF) (Bachani et 
al., 2013) and sera of patients (Falkensammer et al., 2007; Mediouni et al., 
2012), despite otherwise successful treatment with ART. Furthermore, the 
presence of Tat protein and mRNA in the brains of patients has been repeatedly 
documented, where it has been linked to various neurological impairments, 
including HAD and HIVE (Chang et al., 2011; Hofman et al., 1994; Hudson et al., 
2000). 
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The BBB is comprised primarily of brain microvascular endothelial cells 
(BMECs) and secondarily of astrocytes, in coordination with pericytes and other 
cells, as well as important molecular components (including tight junction 
complexes, adherens junction complexes, cellular adhesion molecules [CAMs], 
transporters, and extracellular matrix components), which all combine to form a 
functional, dynamic, semi-permeable barrier designed to protect the brain and 
maintain CNS homeostasis through regulated communication with the periphery. 
In vitro, the reported outcomes of Tat exposure on BMECs demonstrate Tat’s 
ability to target and effectively downregulate the expression of VE-cadherin (a 
major adherens junction complex component) in primary human BMECs 
(hBMECs;(Mishra and Singh, 2013)), as well as that of various tight junction 
proteins (TJPs) in primary hBMECs (Gandhi et al., 2010; Mishra and Singh, 
2013; Xu et al., 2012), in the hCMEC/D3 human BMEC line (Zhong et al., 2008; 
Zhong et al., 2012), and in primary rat BMECs (Andras et al., 2003; Andras et al., 
2005). Tat exposure has also been shown to upregulate expression of the CAMs 
E-selectin (Hofman et al., 1994) and junctional adhesion molecule-2 (JAM-2; 
(Gandhi et al., 2010)), both of which have been identified as important for 
immune cell transmigration, on primary hBMECs. 
Co-culture of primary human astrocytes with primary hBMEC exposed to 
Tat exhibited a significantly compromised BBB, including augmented monocyte 
transmigration across the in vitro BBB model (Gandhi et al., 2010). Furthermore, 
Tat exposure increased MCP-1-dependent transmigration of primary human 
monocytes across an in vitro primary human astrocyte-endothelial cell co-culture 
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model (Weiss et al., 1999). In addition to this, Tat exposure of a primary human 
astrocyte-hBMEC BBB co-culture increased both molecular permeability and 
immune cell transmigration across the barrier (Mahajan et al., 2008). 
Clinically, increased levels of MCP-1 (a strong chemotactic cytokine which has 
been implicated in having a prominent role in HAND) has been observed in the 
brains of patients diagnosed with HIVE (McManus et al., 2000), as well as in the 
CSF and brains of patients diagnosed with HAD (Conant et al., 1998). Increased 
expression of SDF-1 (a different chemotactic cytokine implicated in HAND) has 
also been noted in the brains of patients diagnosed with HAD (Rostasy et al., 
2003). The role of Tat in mediating this increased presence of chemokines in the 
brains of HIV-1-infected patients is supported by in vivo studies which show an 
increase in mRNA and protein expression of MCP-1 (Pu et al., 2003; Toborek et 
al., 2003) and an increase in mRNA expression of SDF-1 (Dutta and Roy, 2015) 
in the brains of mice injected with Tat, as compared to controls. 
The hCMEC/D3 BMEC line has been repeatedly validated in the literature 
for its utilization in the development of in vitro BBB models (Daniels et al., 2013; 
Eigenmann et al., 2013; Hatherell et al., 2011; Huang et al., 2008; Jacob et al., 
2015; Pu et al., 2005; Strazza et al., 2016; Urich et al., 2012; Weksler et al., 
2013). Others have utilized this cell line in Tat exposure experiments, and have 
demonstrated responses of the cell line similar to what has been reported in 
primary hBMEC, including decreased expression of TJP (Zhong et al., 2012) and 
increased mRNA expression of MCP-1 (Huang et al., 2008). However, while prior 
studies demonstrate that Tat alters BBB permeability in various ways, including 
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deregulated expression of TJP, CAM, and cytokines, resulting in enhanced 
immune migration across various BBB models, the role of Tat in the generation 
of chemotactic gradients, an important aspect of immune cell homing for 
transmigration in vivo, has not yet been demonstrated. 
4.3. Materials and Methods 
4.3.1. hCMEC/D3 media formulations, culture and in vitro blood-brain 
barrier generation  
Cells from the human brain microvascular endothelial cell line, hCMEC/D3 
(generously provided by Dr. Babette Weksler), were cultured in endothelial basal 
medium-2 (EBM-2; Lonza) supplemented with heat-inactivated fetal bovine 
serum (FBS; FBS Gold or Sigma-Aldrich; 5%), penicillin-streptomycin (Corning; 
1%), hydrocortisone (Sigma-Aldrich; 1.4 uM), ascorbic acid (Sigma-Aldrich; 5 
ug/mL), chemically defined lipid concentrate (Ceraplex; 1%), HEPES (Corning 
Cellgro; 10 mM), and basic fibroblast growth factor (bFGF; Sigma-Aldrich; 1 
ng/mL); referred to herein as complete hCMEC media. All experiments were 
performed between passages 27 to 32. Cells were grown on collagen-coated 
(Cultrex rat collagen I) 60 cm2 Petri dishes (TPP), 6-well plates (Corning), or 3 
um polycarbonate 3.8 cm2 12-well transwell inserts (Corning). hCMEC/D3 cells 
were seeded at a density of 37,000 cells/cm2 in Petri dishes and 6-well plates, 
and at 45,000 cells/cm2 in 12-well transwell inserts, and grown to functional 
confluence prior to use in experimentation. A serum-free (SF) version of the 
media, made without FBS but inclusive of all other components of the complete 
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hCMEC media, was also made for use in recombinant Tat (rTat) exposures; 
referred to herein as SF hCMEC media. 
4.3.2. P4R5 media formulations and cell culture 
P4 CCR5+ HeLa cells (P4R5 cells), obtained from the NIH AIDS Reagent 
Program (Catalog # 3580), were cultured in Dulbecco’s modification of Eagle’s 
medium (DMEM; Corning Cellgro) supplemented with heat-inactivated FBS 
(Gemini Bioproducts; 10%), penicillin-streptomycin (Corning; 0.4%), kanamycin 
sulfate (Corning; 0.8%), puromycin dihydrochloride (Tocris; 1 ug/ml), and sodium 
bicarbonate (Corning; 0.75%); referred to herein as complete P4R5 media. All 
experiments were performed between passages 7 to 20. Cells were grown and 
passaged in T75 or T150 culture flasks (Greiner bio-one). A serum-free (SF) 
version of the media, made without FBS but inclusive of all other components of 
the complete P4R5 media, was also made for use in rTat-exposures; referred to 
herein as SF P4R5 media.  
4.3.3. Preparation and storage of recombinant HIV-1IIIb Tat1-86 (NIH) 
Recombinant HIV-1IIIb Tat1-86 (rTat) was obtained from the NIH AIDS 
Reagent Program (Catalog # 2222). The lyophilized rTat (at 25 ug) was 
suspended in one milliliter of degassed 100 M dithiothreitol (DTT; Thermo 
Fisher Scientific) in 1 X PBS (Corning Cellgro) under sterile conditions, then 
aliquoted, flash-frozen, and stored at -80C. All rTat work, including all 
experiments, was done utilizing sterile siliconized pipette tips (Bio Plas Inc., and 
VWR) and sterile silanized tubes (Corning) in order to minimize the loss of rTat to 
adherence to plastics. All rTat was also routinely tested and verified for 
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successful transactivation of the HIV-1 LTR via a P4R5 Transactivation Reporter 
Assay (detailed below) prior to use in experimentation.  rTat aliquots were 
thawed on wet ice immediately prior to use in experiments, and any unused 
portion was discarded and not reused. 
4.3.4. Experimental preparation of lipo-rTat, exposure of hCMEC/D3 
cultures and collection of conditioned media 
For preparation of recombinant lipo-Tat (lipo-rTat) for exposure of 
hCMEC/D3 cells, rTat was complexed to Lipofectamine 2000 reagent 
(Invitrogen), per the manufacturer’s protocol, prior to use. Immediately prior to 
exposure experiments, all chambers of hCMEC/D3 cells that had been grown to 
functional confluence on 12-well transwell inserts were washed twice with 
warmed 10 mM HEPES (Corning) in 1X HBSS (Corning), followed by addition of 
vehicle or lipo-rTat in SF hCMEC media at the indicated experimental 
concentrations. At the times indicated, conditioned media from both chambers of 
exposed transwells were harvested, flash-frozen and stored until utilized to 
assess cytokine expression profiles by ELISA (detailed below). 
4.3.5. Heat-inactivation of recombinant HIV-1IIIb Tat1-86 
Heat-inactivation of rTat was performed by placing a thawed aliquot of 
rTat on a pre-heated heat block at 85C for 60 minutes. This protocol is reported 
to inactivate proteins, but not endotoxins, which may be a contaminate of rTat, 
which was made in E. coli.  
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4.3.6. P4R5 LTR trans-activation reporter assay 
P4R5 cells were seeded in 96-well plates (Falcon) at densities of either 
2.2 X 10^4 cells/well (if used in 24 hours) or 1.2 X 10^4 cells/well (if used in 48 
hours); after culture, cells were washed with 1X PBS and exposed to either mock 
exposure conditions, transfection with an HIV-1IIIb Tat1-86 plasmid (with 
Lipofectamine 2000, per the manufacturer’s protocol), or exposure to naked rTat 
or lipo-rTat, at the concentrations indicated, in SF P4R5 media. After 6 hours, 
FBS was added to all wells, and replaced in the incubator for an additional 18 
hours. After 24 hours of total exposure, cells were washed with 1X PBS and 
immediately assayed for LTR-B-galactosidase reporter expression with the 
standardized Tropix Galacto Star Chemiluminescent Reporter Assay kit (A & B 
Systems), per the manufacturer’s protocol. 
4.3.7. FITC-dextran permeability assay 
Monolayers of hCMEC/D3 cells grown to functional confluence on 3 M 
polycarbonate transwell inserts were exposed to treatment conditions (detailed 
below), or for 30 minutes with 1.4 M mannitol (positive control for assay). At time 
zero, all chambers were washed with warmed 10 mM HEPES in 1X HBSS, 
followed by addition of plain EBM-2 media to bottom chambers and 2 mg/ml of 
70 kD FITC-dextran (Sigma-Aldrich; in plain EBM-2 media) to top chambers. At 
5-minute intervals up to 30 minutes, and at 60, 90, and 120 minutes, all bottom 
chambers were sampled, with a 100 l volume transferred to a white-walled 
optical-bottom 96-well plate. Fluorescence intensity was read and utilized to 
calculate permeability coefficients for each treatment condition.  
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4.3.8. MCP-1 and SDF-1 ELISAs  
Monolayers of hCMEC/D3 cells grown to functional confluence on 3 M 
polycarbonate transwell inserts were exposed to vehicle or rTat at the indicated 
concentrations and incubation periods. At time-zero, conditioned media from both 
transwell chambers were collected and assayed by ELISA for cytokine analysis. 
Standardized kits for MCP-1 (eBioscience) and SDF-1 (R & D Systems) were 
utilized to determine cytokine concentrations of transwell chambers, following 
manufacturers’ protocols. 
4.3.9. Statistics 
Statistics were calculated utilizing Microsoft Excel and GraphPad Prism 
version 6.0. Unpaired Student’s t-tests were performed to assess significance.  
4.4. Results 
4.4.1. hCMEC/D3 cells form a confluent barrier on polycarbonate 
transwells after 6 days and remain stably confluent up to 96 
hours in serum-free media. 
One of the nuances of working with recombinant Tat (rTat) is that it can 
become bound and inactivated in the presence of serum proteins, necessitating 
that experiments be performed under serum-free (SF) conditions. Therefore, in 
order to determine if the hCMEC/D3 cultures grown on transwells would maintain 
functional confluence throughout the course of rTat-exposures, experiments were 
done to assess the rate of tracer molecule passage across hCMEC/D3 transwells 
under SF conditions. hCMEC/D3 cells were initially cultured in complete hCMEC 
media for 6 days. All chambers were then washed twice with warmed 10 mM 
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HEPES in 1X HBSS and then a media change with SF hCMEC media was 
performed. FITC-dextran permeability assays were then performed at the 
indicated time-points in order to calculate permeability coefficients (Pe) for 
hCMEC cultured in SF conditions for 2, 24, 48, 72, and 96 hours. A 30-minute 
mannitol treatment on control wells prior to time-zero for each SF time-course 
served as a positive control for BBB compromise. Results from the permeability 
assay show that culture in SF media for up to 96 hours after they were cultured 
to functional confluence, did not alter the basal rate of tracer molecule passage 
across these cells (Figure 4.1). 
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Figure 4.1. hCMEC/D3 cells form a confluent barrier on polycarbonate 
transwells after 6 days and remain stably confluent up to 96 hours in 
serum-free media. hCMEC/D3 cells cultured on collagen-coated 3 M 
polycarbonate transwell inserts were cultured for 6 days in complete hCMEC 
media to functional confluence, then all chambers were washed twice with 
warmed 10 mM HEPES in 1X HBSS.  Then a media change with SF hCMEC 
media was performed. Cells were then cultured in SF hCMEC media for a total of 
2, 24, 48, 72, or 96 hours. Mannitol was incubated on control cells 30 minutes 
prior to time-zero for each exposure course. Following incubation with SF media, 
all chambers were washed and permeability was assessed by determining the 
amount of 70 kDa FITC-dextran to pass from the upper to lower chambers over 
30 minutes. Permeability coefficient (Pe) was calculated. All courses were 
performed in triplicate and are representative of two independent experiments. 
Based on 95% confidence intervals no significant change was observed with any 
of the experimental exposure conditions. Mannitol treatment *** p<0.0001. 
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Figure 4.1. 
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4.4.2. Recombinant HIV-1IIIb Tat1-86 (complexed with Lipofectamine 
2000) efficiently trans-activates the P4R5 LTR, which is 
abrogated by heat-inactivation. 
In order to confirm that the rTat being utilized in experiments was 
functionally active after preparation and storage, LTR trans-activation reporter 
assays were performed wherein P4R5 cells were exposed to serially-diluted rTat, 
either without complex to Lipofectamine 2000 (“naked rTat”) or with complex to 
Lipofectamine 2000 (“lipo-rTat”) in SF P4R5 media. After 24 hours of total 
exposure, cells were washed twice with 1X PBS and immediately assayed for 
LTR-B-galactosidase reporter expression. The results from the reporter assay 
show that complexing of rTat with the cationic liposome formulation is necessary 
for its efficient trans-activation of the P4R5 LTR, as no concentrations of naked 
rTat were able to trans-activate the P4R5 LTR above mock levels (Figure 4.2.A). 
The data also showed that heat-inactivation of rTat, abrogated its ability to trans- 
activate the P4R5 LTR (Figure 4.2.A). The optimization of the heat-inactivation 
protocol is demonstrated in Figure 4.2.B.  
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Figure 4.2. Recombinant HIV-1IIIb Tat1-86 (complexed with Lipofectamine 
2000) efficiently trans-activates the P4R5 LTR, which is abrogated by heat-
inactivation. P4R5 cells were seeded in 96-well plates and cultured for 24 or 48 
hours. Cells were then washed with 1X PBS, followed by exposure to either 
mock exposure conditions, transfection with an HIV-1IIIb Tat1-86 plasmid 
(transfected with Lipofectamine 2000), or exposure to naked rTat or lipo-rTat, at 
the concentrations indicated, in SF P4R5 media. After 6 hours, FBS was added 
to all wells and the plate was incubated for an additional 18 hours. After 24 hours 
of total Tat exposure, cells were washed with 1X PBS and immediately assayed 
for LTR-B-galactosidase reporter expression with the Tropix Galacto Star 
Chemiluminescent Reporter Assay kit. (A) Comparison of lipo-rTat versus naked 
rTat in ability to transactivate the P4R5 LTR. (B) Heat-inactivation of rTat was 
performed by placing thawed aliquots of rTat on pre-heated heat blocks at the 
indicated temperatures and times; in this manner, the heat-activation protocol 
was optimized for further use as a control in rTat exposure experiments. 
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Figure 4.2. 
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4.4.3. Exposure to intact recombinant HIV-1IIIb Tat1-86 does not 
induce MCP-1 gradients from hCMEC BBB transwells. 
We previously demonstrated that repeated administrations of morphine (a 
drug of both clinical and addictive significance in HIV-1-infected populations) on 
hCMEC/D3 transwells resulted in the generation of chemotactic gradients of both 
MCP-1 and SDF-1 across the in vitro BBB model (Chapter 3). In order to address 
the potential role of Tat exposure in the generation of chemotactic gradients by 
the BBB, hCMEC/D3 monolayers cultured on 3 M polycarbonate transwells 
were exposed to either vehicle, lipo-rTat or naked rTat, in SF hCMEC media at 
the indicated concentrations and conditions, for 12 and 24 hours. Tat levels have 
been reported in the range of 100-200 ng/ml in both the CSF (Westendorp et al., 
1995) and sera (Xiao et al., 2000) of patients, however, it is estimated that local 
concentrations of Tat in brain and other tissue may be much higher that this 
owing to Tat’s susceptibility to be bound by various tissue surface proteins, thus 
lowering its ability to be detected in vivo (Andras et al., 2003; Norman et al., 
2008). In the present studies, Tat concentrations of 100 ng/ml, 200 ng/ml, and 
500 ng/ml were utitlized. Conditioned media from the apical and basal chambers 
were assayed for cytokine expression of MCP-1 (CCL2) by ELISA. The data 
demonstrated that exposure to naked rTat at any concentration, condition, or 
time-point did not alter the secretion of MCP-1 from hCMEC/D3 cells, as 
compared to vehicle controls (Figure 4.3.A-D). Interestingly, the data also 
indicates that hCMEC/D3 exposed for 24 hours (but not 12 hours) to rTat that 
had undergone the heat-inactivation protocol and then complexed to 
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Lipofectamine 2000 (“heat-inactivated lipo-rTat”) resulted in increases in basal 
chamber concentrations of MCP-1, resulting in the generation of chemotactic 
gradients of this cytokine (Figure 4.3.E-H); however, hCMEC/D3 exposed to 
intact lipo-rTat did not generate similar gradients at the 24-hour time-point 
(Figure 4.3.G-H).  
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Figure 4.3. Exposure to intact recombinant HIV-1IIIb Tat1-86 does not 
induce MCP-1 gradients from hCMEC BBB transwells. hCMEC/D3 
monolayers on collagen-coated 3 M polycarbonate transwells were incubated 
with vehicle, lipo-rTat or naked rTat, in SF hCMEC media at the indicated 
concentrations, for 12 (A, B, E, F) or 24 (C, D, G, H) hours. Conditioned media 
from apical and basal chambers were harvested and assayed for cytokine 
expression profiles by ELISA. MCP-1 protein levels were measured and 
analyzed. Graphed are raw pg/ml values (A, C, E, G) and fold-change of pg/ml 
values from chambers within each treatment condition (B, D, F, H). Bars 
represent triplicates of individual experiments +/- SD. ****p≤0.0001, as 
determined by student’s t-test. 
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Figure 4.3 
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4.4.4. Exposure to heat-inactivated recombinant HIV-1IIIb Tat1-86 
complexed with Lipofectamine 2000 induces cytokine 
gradients across the in vitro human BBB model.  
In order to address whether longer exposures with intact lipo-rTat would 
stimulate the generation of chemotactic gradients in the in vitro BBB model, 
hCMEC/D3 transwells were exposed to either vehicle, intact lipo-rTat, or (heat-
inactivated) lipo-rTat peptides, in SF hCMEC media at the indicated 
concentrations for 48 and 72 hours. Conditioned media from the apical and basal 
chambers were assayed for cytokine expression of MCP-1 (CCL2) and SDF-1 
(CXCL12) by ELISA. The data demonstrate that exposure to intact lipo-rTat at 
any concentration or time-point did not alter the secretion profiles of MCP-1 
(Figure 4.4.A-D) or SDF-1 (Figure 4.4.E-F) from hCMEC/D3 cells, as compared 
to vehicle controls. Similarly to what was observed at the 24-hour time-point 
(Figure 4.3.G-H), the data here also shows that hCMEC/D3 exposed to rTat that 
had undergone the heat-inactivation protocol and then complexed to 
Lipofectamine 2000 (“heat-inactivated lipo-rTat”) for either 48 or 72 hours, 
resulted in the generation of chemotactic gradients of both MCP-1 (Figure 4.4.A-
D) or SDF-1 (Figure 4.4.E-F) across the in vitro BBB system. 
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Figure 4.4. Exposure to heat-inactivated recombinant HIV-1IIIb Tat1-86 
complexed with Lipofectamine 2000 induces cytokine gradients across the 
in vitro human BBB model. hCMEC/D3 monolayers on collagen-coated 3 M 
polycarbonate transwells were incubated with vehicle, intact lipo-rTat, or (heat-
inactivated) lipo-rTat peptides, in SF hCMEC media at the indicated 
concentrations for 48 (A-B) and 72 (C-F) hours. Conditioned media from apical 
and basal chambers were harvested and assayed for cytokine expression 
profiles by ELISA. MCP-1 (A-D) or SDF-1 (E-F) protein levels were measured 
and analyzed. Graphed are raw pg/ml values (A, C, E) and fold-change of pg/ml 
values from chambers within each treatment condition (B, D, F). Bars represent 
triplicates of individual experiments +/- SD. *p≤0.01, **p≤0.001, ***p≤0.0001, 
****p≤0.00001, as determined by student’s t-test. 
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Figure 4.4. 
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4.4.5. Exposure to recombinant HIV-1IIIb Tat1-86 does not alter the basal 
rate of tracer molecule passage across hCMEC/D3 BBB cells.  
In order to determine if exposure to lipo-rTat was inducing leakiness of the 
hCMEC/D3 BBB beyond a normal baseline level, permeability of the in vitro BBB 
under the various exposure conditions was assessed by a FITC-dextran 
permeability assay. A 30-minute mannitol treatment on control wells prior to time 
zero for the exposure course served as a positive control for BBB compromise. 
Results from the permeability assay show that exposure with any concentration 
or condition (intact versus heat-inactivated) or incubation time with lipo-rTat did 
not increase baseline leakiness of the monolayer, as compared to vehicle 
controls (Figure 4.5). 
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Figure 4.5. Exposure to recombinant HIV-1IIIb Tat1-86 does not alter the 
basal rate of tracer molecule passage across hCMEC/D3 BBB cells. 
hCMEC/D3 cells cultured on collagen-coated 3 M polycarbonate transwell 
inserts were either incubated with vehicle, intact lipo-rTat, or (heat-inactivated) 
lipo-rTat peptides, in SF hCMEC media at the indicated concentrations for 24 (A-
B), 48 (C-D), or 72 (E-F) hours. Mannitol was incubated on control cells 30 
minutes prior to time-zero for each exposure course. Following exposure, all 
chambers were washed and permeability was assessed by determining the 
amount of 70 kDa FITC-dextran to pass from the upper to lower chambers over 
120 minutes. Permeability coefficient (Pe; A, C, E) and raw fluorescence intensity 
(RFI; B, D, F) were calculated. All courses were performed in triplicate. Based on 
95% confidence intervals no significant change was observed with any of the 
experimental exposure conditions. Mannitol treatment **** p<0.0001. 
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Figure 4.5. 
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4.5. Discussion 
In the studies presented herein, the hCMEC/D3 BMEC line was utilized to 
generate an in vitro BBB model in order to assess the effects of recombinant 
HIV-1IIIb Tat1-86 exposure on BBB endothelial cells. Culture of hCMEC/D3 
confluent monolayers under serum-free conditions for up to 96 hours did not alter 
the basal rate of tracer molecule passage across the in vitro BBB (Figure 4.1), an 
important control for rTat-exposure experiments as rTat can become bound and 
inactivated in the presence of serum proteins found in conventional laboratory-
grade serum such as FBS. An additional control experiment to confirm the rTat 
being utilized in the hCMEC/D3 exposures was functionally active (after the 
lyophilized product provided by the NIH AIDS Reagent Program had undergone  
a reconstitution and storage protocol) was use of the rTat in P4R5 LTR Trans-
activation Reporter Assays (Figure 4.2); these experiments also confirmed a 
previously published finding which indicates that complexing of rTat with a 
cationic liposome formulation (such as Lipofectamine 2000), assists in rTat’s 
ability to efficiently enter and transcriptionally influence cells, as compared to 
naked rTat (Li et al., 2012a).  
Because it has been repeatedly suggested in the literature that some of 
Tat’s in vivo effects may be mediated through Tat binding to extracellular 
receptors, such as vascular endothelial growth factor receptor 2 (VEGFR2) or N-
methyl D-aspartate receptor (NMDAR), both of which are expressed on human 
BMECs (Andras et al., 2007; Chen et al., 2016; Davis et al., 2010; Fearnley et 
al., 2016; Holmes et al., 2007; Hudson et al., 2014; Reijerkerk et al., 2010; Sharp 
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et al., 2003; Sharp et al., 2005), experiments were performed with naked rTat, as 
well as the lipo-rTat. It was found that exposure of the apical side of hCMEC/D3 
transwells (simulating exposure from the peripheral blood circulation) to 
increasing biologic concentrations of intact naked rTat or lipo-rTat did not alter 
the cytokine profiles of the hCMEC/D3 transwells, as compared to vehicle 
controls (Figures 4.3 and 4.4). Curiously, however, the data also demonstrated 
that incubation of hCMEC/D3 with heat-inactivated lipo-rTat (i.e. rTat that had 
undergone the heat-inactivation protocol and subsequently complexed with 
Lipofectamine 2000) resulted in the generation of chemotactic gradients of both 
MCP-1 and SDF-1 across the in vitro BBB (Figures 4.3 and 4.4); this was an 
unexpected finding, as heat-inactivation of rTat is a standard negative control 
commonly found in the primary rTat literature for experiments, and served as the 
appropriate negative control for the P4R5 LTR Trans-activation Reporter Assay 
(Figure 4.2). It was also determined that exposure to either intact lipo-rTat or 
heat-inactivated lipo-rTat did not induce an increase in the baseline leakiness of 
the hCMEC monolayer, as compared to vehicle controls (Figure 4.5). 
 A potential explanation for the unexpected results observed in the cytokine 
data is that heat-inactivation/boiling of rTat is generating peptides of Tat, which 
(when complexed with Lipofectamine 2000 to generate lipo-rTat) are triggering 
toll-like receptor (TLR) pathways and thus generating chemotactic gradients. This 
theory is supported by findings in the literature which demonstrate that Tat has 
been shown to activate TLR2 in T cells, and that activation of TLR2 and/or TLR4 
is important in the expression of SDF-1 in vivo, as knock-out TLR2 or TLR4 mice 
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expressed significantly diminished levels of SDF-1 in their brains, as compared to 
wild-type littermates (Dutta and Roy, 2015). Further, TLR4 activation in myeloid-
lineage cells by Tat has also been shown (Ben Haij et al., 2015; Planes et al., 
2016; Planes et al., 2014), and TLR4 activation has been linked to increased 
expression of SDF-1 in vivo (Dutta and Roy, 2015; Yang et al., 2015) and 
enhanced secretion of MCP-1 from endothelial cells in vitro (Ishikado et al., 2009; 
Kang et al., 2009; Pirvulescu et al., 2014; Zeuke et al., 2002). Furthermore, both 
in vivo activation of TLR2 (Mottahedin et al., 2017) and in vitro activation of TLR4 
(Paradis et al., 2016) were shown to enhance immune cell transmigration across 
the BBB; this is an important observation in the context of HIV-1 CNS disease, 
which is believed to at least partially be mediated by an influx of HIV-1-infected 
and/or activated immune cells into the brain. Despite these interesting 
observations, however, it does not appear that intact rTat is capable of inducing 
the generation of chemokine gradients across the in vitro BBB model at the 
concentrations tested, as was observed in our morphine data (Chapter 3). And 
whether the generation of chemotactic gradients by lipo-rTat peptides is a 
biologically relevant modeling of how Tat may stimulate processes in endothelial 
cells of the BBB in vivo remains to be determined.  
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5.1. Overall summary  
The studies presented in this doctoral dissertation utilized the hCMEC/D3 
brain microvascular endothelial cell (BMEC) line in the development of an in vitro 
blood-brain barrier (BBB) model, and examined the biochemical and molecular 
effects of the mu-opioid morphine and the HIV-1 protein Tat on this in vitro BBB 
model system. In Chapter 2, it was demonstrated that hCMEC/D3 cells express 
MOR-1 (the primary morphine receptor identified and described in the primary 
literature), as well as UGT2B7 (the sole morphine-metabolizing enzyme reported 
in the literature) (Figure 2.4.C); however, it was observed that this cell line did not 
produce detectable levels of morphine metabolites (Figures 2.4 and 2.5, and 
Table 2.1), despite confirmed expression of UGT2B7. This suggests that 
UGT2B7 may not be functional in endothelial cells of the BBB. Transport of 
morphine across hCMEC/D3 in vitro BBB transwells was also observed (Figures 
2.4 and 2.5), however, pre-treatment with an inhibitor of p-glycoprotein 
(zosuquidar) did not prevent internalization of morphine into cells (Figure 2.5.C 
and Table 2.1), nor did it significantly delay transport of morphine across the in 
vitro BBB (Figure 2.5.C), despite p-glycoprotein’s suggested role in the transport 
of morphine across the BBB in the primary literature. In addition, pre-treatment 
with a MOR-1 antagonist (naloxone) also did not prevent entry of morphine into 
hCMEC/D3 cells (Figure 2.5.B and Table 2.1). This altogether suggests that 
other receptors or transporters, not explored in these studies, may be involved in 
the entry and transport of morphine across BBB endothelial cells. 
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 In Chapter 3, surface expression of MOR-1 was confirmed (Figure 3.3.A), 
and repeated administrations of morphine over 72 hours resulted in the 
increased surface expression of MOR-1 on hCMEC/D3 (Figure 3.3.C); however, 
administration of morphine over 24 hours did not change MOR-1 surface 
expression (Figure 3.3.B). A curious finding which, combined with the 
observations made in Chapter 2, suggests that morphine may be acting through 
a non-MOR-1 mechanism in BBB endothelial cells. It was also demonstrated in 
this chapter that repeated administrations of morphine onto hCMEC/D3 cultures 
resulted in downregulation of TJP mRNA expression over 72 hours of total 
exposure (Figure 3.1). In addition, it was shown that repeated (but not single) 
administrations of morphine resulted in the generation of chemotactic gradients 
of MCP-1 and SDF-1 across the in vitro BBB model over 24, 48, and 72 hours 
(Figure 3.4), a finding not previously reported in the literature. Taking these 
points into consideration, these findings support the notion that mu opioid intake 
by patients and/or addicts may be worsening some aspects of CNS disease 
pathologies, including those implicated in HAND, related to increased 
inflammation and infiltration of infected and/or activated immune cells into the 
CNS. 
 In Chapter 4, it was found that exposure of hCMEC/D3 cells to intact 
naked rTat or lipo-rTat did not result in the generation of chemotactic gradients of 
either MCP-1 or SDF-1 at any of the time-points or concentrations tested 
(Figures 4.3 and 4.4), despite confirmed activity of rTat by P4R5 LTR Trans-
activation Reporter Assays prior to use in all experiments (Figure 4.2). This 
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suggests that although HIV-1 Tat has been repeatedly shown to deregulate the 
BBB in various ways, induction of chemotactic gradients may not be one of the 
predominant mechanisms by which it compromises the BBB and contributes to 
CNS disease in HAND. Curiously, it was also found that exposure of hCMEC/D3 
transwells to rTat that had undergone the heat-inactivation protocol and then 
complexed with Lipofectamine 2000 (heat-inactivated lipo-rTat) stimulated the 
generation of gradients of MCP-1within 24 hours (Figure 4.3) and of SDF-1 within 
72 hours (Figure 4.4); it is speculated that this may be due to the stimulation of 
TLR2 and/or TLR4 pathways by the lipo-rTat peptides. Whether this is a 
biologically relevant model of how Tat may stimulate processes in endothelial 
cells of the BBB, however, remains to be determined. 
5.2. Future directions 
Due to the results observed in Chapters 2, 3, and 4, it became apparent 
that there are additional lines of questioning that can and should be investigated 
in order to more thoroughly elucidate the findings of this research. The following 
studies are proposed, to that end: 
Future studies for chapter 2: 
 In order to determine if there are other inhibitors involved in the transport 
of morphine across the BBB, pre-treatment of hCMEC/D3 with a more 
broad-spectrum transporter inhibitor should be tested in order to 
determine if this will inhibit transport of morphine across the hCMEC/D3 in 
vitro BBB model. Such broader spectrum inhibitors may include verapamil 
or cyclosporine A—both of which have been utilized in the primary 
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literature and attributed to inhibition of p-glycoprotein; however, these are 
not exclusive to p-glycoprotein inhibition, and thus may reveal that there is 
indeed a different (however, not yet identified) transporter involved in the 
process of morphine transport. 
 A caveat to the use of a cell line is that certain biochemical aspects may 
be altered as compared to primary cells of a similar lineage. In order to 
determine if the absence of morphine metabolites generated by 
hCMEC/D3 cultures are due to a caveat of the cell line, similar studies 
should be performed with primary BMECs in order to determine if 
morphine metabolites are generated by primary BMECs under similar 
hCMEC/D3 culture conditions.  
 A co-culture of BMEC with astrocytes, which would represent a more 
biologic BBB model, may result in different observations with regards to 
morphine transport and/or metabolism. In order to determine if the addition 
of astrocytes would alternatively impact these processes, similar 
experiments should be performed in co-culture models. 
 An interesting caveat to this model may be that the culture conditions, 
although optimized for most general use for in vitro experiments, do not 
adequately reflect the biologic environment of an in vivo BBB, and thus 
may be missing certain naturally-occurring molecular components 
necessary to assist in the generation of morphine metabolites. In the case 
of UGT2B7, this enzyme catalyzes a glucuronidation reaction, the addition 
of glucuronic acid to a molecule via a glycosidic linkage resulting in 
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glucuronides. An additional experiment to consider may be to supplement 
the media with concentrations of glucuronic acid in order to determine if 
this input may result in the necessary combination of substrates needed to 
generate the expected metabolites. 
 In order to test our methodology and technique in these experiments, 
positive controls for morphine metabolism, such as morphine exposure of 
liver cell cultures (involved in the first-pass metabolism of morphine in the 
human body), or primary microglia cultures [a specialized CNS cell type 
involved in immune surveillance, which have been shown to effectively 
metabolize morphine and produce the primary morphine metabolites M3G 
and M6G in vitro (Togna et al., 2013)], would be appropriate to confirm 
that we have properly processed samples for this type of experimental 
assessment. 
Future studies for chapter 3 
 Given that neither morphine nor naloxone are specific to activation or 
inhibition of MOR-1, studies should be performed in order to determine if 
morphine’s effects in alterations of TJP mRNA, as well as in the 
generation of chemotactic gradients of MCP-1 and SDF-1 are mediated by 
TLR4 activation, versus MOR-1 activation, by morphine. This can be 
tested by specific-stimulation with receptor-specific agonists (such as M3G 
or LPS for TLR4 and M6G for MOR-1) in the hCMEC/D3 model. In 
addition, pre-treatment with receptor-specific inhibitors to either or both of 
these receptors in the presence of morphine, may further narrow down 
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whether these effects are mediated predominantly by either, or partially by 
both. 
 As mentioned for chapter 2, caveats of the cell line lead us to question if 
similar results will be observed in a primary culture system. Therefore, in 
order to determine if the observed chemotactic gradients generated in 
response to morphine exposure of hCMEC/D3 are due to nuances of the 
cell line, similar studies should be performed with primary BMEC in order 
to determine if similar gradients are generated by morphine exposure of a 
primary BMEC BBB model. A version of these experiments should also be 
done with co-culture with astrocytes, as this would represent a more 
biologic BBB model. 
 It is presumed that the generation of chemotactic gradients will result in 
the increased transmigration of immune cells across the BBB, which 
would have implications for CNS disease, including those observed in 
HAND. We attempted the modeling of immune cell transmigration across 
hCMEC/D3, however, were unable to overcome technical setbacks and 
limitations in the current model, and a recommendation was made recently 
by a collaborator that this particular cell line may not be adequate for 
attempting to model immune cell transmigration. Therefore, experiments 
should be done in a primary BMEC model in order to determine if and how 
the generation of these gradients will affect immune cell transmigration 
across the in vitro BBB model.  
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 It is noted that in light of a lack of degradation or metabolism of morphine 
by hCMEC/D3 cultures (Chapter 2), it may be possible that some of the 
observed effects in Chapter 3, particularly those conducted in 6-well 
dishes, are reflective of effects of tolerance of MOR-1 or other receptors in 
the presence of continuous exposure/stimulation with morphine. In order 
to test if this is the case, experiments and assays should be performed 
after similar exposure concentrations, and spike-versus-no spike, but with 
morphine washed off after individual incubations. 
Future studies for chapter 4: 
 Given the lack of chemotactic gradients observed in response to exposure 
of hCMEC/D3 with intact rTat, studies should be performed in order to 
determine if naked rTat versus lipo-rTat exposure may result in other 
biochemical or molecular deregulation of the in vitro BBB model, such as 
alterations in expression levels of tight junction complex components, cell 
adhesion molecules, and other cytokines. 
 Also, given the results observed wherein what was supposed to be the 
negative control (i.e. heat-inactivated rTat) resulted in the generation of 
chemotactic gradients, experiments should be performed in order to test 
alternatives for a Tat negative control, such as immunoabsorption of Tat 
with antibodies. 
 It is noted that the recombinant Tat exposures in Chapter 4 were 
performed on the apical chamber of the hCMEC/D3, modeling exposure of 
the luminal side of the endothelium to Tat circulating in the periphery. 
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However, Tat can also be produced by infected CNS cells, notably 
monocytes, perivascular macrophages, microglia, and possibly astrocytes. 
Therefore, Tat exposure of the basal chamber of hCMEC/D3 cultures 
should be performed in order to determine if exposure of the CNS side of 
the endothelium by Tat would result in deregulation of the in vitro BBB 
model. 
 In addition to this, recombinant Tat generated in E. coli is considered to be 
approximately 1000-fold less biologically active than Tat made and 
secreted from Tat-transfected cells (Li et al., 2008). However, there is no 
current evidence in the literature to demonstrate that BMEC are infected 
by HIV-1. Thus, it may be necessary to perform experiments in which 
astrocyte cultures (or other relevant CNS cultures) are transiently 
transfected with Tat plasmids, and to then expose hCMEC/D3 cultures to 
these conditioned media in order to observe Tat-mediated effects in this 
BMEC line. 
5.3. Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in 
HIV-1 Disease 
Numerous in vitro and in vivo models have demonstrated molecular 
deregulation and functional impairment of the BBB in the context of HIV-1 
infection, including downregulation of key tight junction complex components and 
upregulation of cell adhesion molecules on BMECs, aberrant activation of 
astrocytes and pericytes, overall increased permeability, and enhanced immune 
cell passage across the barrier (Toborek et al., 2005; Li et al., 2009; Roberts et 
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al., 2010; Debaisieux et al., 2012; Louboutin and Strayer, 2012; Nakagawa et al., 
2012; Bagashev and Sawaya, 2013; Niu et al., 2014; Rao et al., 2014; Hong and 
Banks, 2015; Maubert et al., 2015). However, while multiple HIV-1 proteins 
(including Tat, gp120, Vpr, and Nef) have been shown to deregulate numerous 
pathways resulting in damage to the BBB, the role of HIV-1 in modulating the 
pathways relative to the repair of the BBB and re-endothelialization (or the 
inhibition, thereof) have not yet been reported in detail. Taking these points into 
consideration, we reviewed the literature for what is known and reflected on 
some of the most pressing questions with regards to this topic, proposing a 
hypothetical model of the mechanisms underlying delayed blood-brain barrier 
repair in HIV-1 infection: 
The blood-brain barrier (BBB) is a complex network of microvasculature, 
comprised primarily of brain microvascular endothelial cells (BMECs), astrocytes, 
and pericytes, which regulates cellular, macromolecule, and metabolite passage 
between the peripheral circulation and the central nervous system (CNS). 
Damage to the BBB has been linked to neurocognitive deficits sustained in 
multiple diseases, including stroke, Alzheimer's Disease, and numerous 
infections, including human immunodeficiency virus type 1 (HIV-1) (Krizanac-
Bengez et al., 2004; Salmina et al., 2010; Logsdon et al., 2015). Although the 
development and deployment of anti-retroviral therapy (ART) has transformed 
HIV-1 infection from an acute terminal diagnosis to a chronic pharmaceutically-
managed clinical condition (in the developed world), many clinical complications 
remain prevalent in HIV-1-infected patients, including the spectrum of 
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neurocognitive deficits collectively termed HIV-1-associated neurocognitive 
disorders (HAND). While the current age of ART has decreased the occurrence 
of the more severe manifestations of neurocognitive impairment in patients, 
particularly with regards to the incidence of HIV-1-associated dementia (HAD), 
the overall prevalence of HAND has not subsided (Cysique et al., 2004; 
Robertson et al., 2007; Tozzi et al., 2007; Heaton et al., 2010, 2011; Cysique and 
Brew, 2011). In fact, it is currently estimated that nearly 50–70% of HIV-1-
infected patients on a successful ART regimen experience some level of 
neurocognitive decline (Heaton et al., 2010, 2011, 2015; Simioni et al., 2010; 
Obermeit et al., 2017). Implicated in the development of HAND in patients is a 
combination of toxic viral proteins released into the CNS, a sustained host pro-
inflammatory response in the CNS initiated by the virus, deregulated endogenous 
small molecule metabolism, detrimental metabolic byproducts associated with 
combination ART, as well as certain types of HIV-1 genetic variants that may 
cause some of these pathogenic processes (Krebs et al., 2000; Wang et al., 
2006; Ferrucci et al., 2011, 2012; Strazza et al., 2011; Dahiya et al., 2013; 
Aiamkitsumrit et al., 2014; Gresele et al., 2014; Maubert et al., 2015; Dampier et 
al., 2017; James et al., 2016). 
Clinically, endothelial cell dysfunction and general wound repair has been 
problematic in the HIV-1-infected patient population, with several reports 
highlighting delays in healing time and related complications, including secondary 
infections of these wounds (Lord, 1997; Davis et al., 1999; Diz Dios et al., 1999; 
Miyamoto et al., 2006; Arildsen et al., 2013; Wang et al., 2013; Francisci et al., 
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2014; Balsam et al., 2015; Fitzpatrick et al., 2016). While the mechanisms 
orchestrating endothelial repair, particularly considering those of the BBB, are not 
entirely defined, some molecular effectors and interconnecting pathways have 
been identified in the literature for their demonstrated involvement in repair 
processes in various model systems. In particular, cellular Src kinase (c-Src), a 
ubiquitously expressed member of the Src family of non-receptor tyrosine 
kinases, has a defined role in endothelial cell regulation and repair, both in vitro 
and in vivo (Takenaga et al., 2009; Liu et al., 2010; Franco et al., 2013; Bai et al., 
2014; Cao et al., 2015), the specifics of which are described below. Importantly, 
c-Src is involved in pathways linked to the activation of vascular endothelial 
growth factor receptor 2 (VEGFR2) and N-methyl D-aspartate receptor 
(NMDAR), both of which are expressed on human BMECs and with 
demonstrated roles in BBB regulation and integrity (Sharp et al., 2003, 2005; 
Andras et al., 2007; Holmes et al., 2007; Davis et al., 2010; Reijerkerk et al., 
2010; Hudson et al., 2014; Chen et al., 2016; Fearnley et al., 2016). 
Of note, HIV-1 infection and c-Src activation have been shown to have a 
reciprocal relationship in the literature with reports demonstrating that c-Src 
activation was increased in human Jurkat T cells 24 h after HIV-1 infection 
(Phipps et al., 1996) and in activated primary human CD4 T cells within 1 h of 
infection, as compared to uninfected controls, and that both chemical inhibition 
and siRNA knockdown of c-Src decreased infectivity of Nef-deficient HIV-1 
reporter viruses by more than 50% in primary human CD4 T cells, in vitro 
(McCarthy et al., 2016). In addition, siRNA knockdown of c-Src decreased 
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proviral integration of Nef-competent X4 and R5 HIV-1 laboratory strains by 
several-fold and significantly attenuated replication of these viral strains in 
primary human CD4 T cells, in vitro (McCarthy et al., 2016). While this 
observation links c-Src to HIV-1 infection in cells, it is known that BMECs and 
endothelial cells in general are not infected. 
Given this point, it is more likely that extracellular viral proteins would 
interact with the BMECs causing dysfunction or inhibiting repair. At the level of 
isolated viral proteins, previous reports have indicated that HIV-1 gp120 can 
activate the NMDAR through direct binding of NMDAR subunits (Xin et al., 1999) 
in numerous in vitro systems, including in primary rat (Pattarini et al., 1998) and 
human (Pittaluga et al., 1996) neuronal synaptosomes; indirect activation of the 
NMDAR by gp120 exposure through the enhanced secretion of NMDAR agonists 
from proximal glia (Meucci and Miller, 1996) as well as activation of other 
receptor-mediated pathways which affect NMDAR activity in primary rat cultures 
(Xu et al., 2011) has also been reported. Additionally, it has been demonstrated 
that HIV-1 Nef activates c-Src in an in vitro yeast model system (Trible et al., 
2006; Narute and Smithgall, 2012). Most strikingly, though, c-Src, VEGFR2, and 
NMDAR have all been shown to be activated by exposure to HIV-1 Tat protein in 
a number of cell types, suggesting that Tat may be involved in inhibiting the 
mechanisms of BBB repair in HIV-1 disease. With respect to Tat, this may be of 
particular importance in ART-suppressed patients given recent evidence that 
shows Tat can be detected in cells, cerebral spinal fluid, and plasma of these 
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individuals (Falkensammer et al., 2007; Mediouni et al., 2012; Bachani et al., 
2013). 
To further support the role of c-Src in BBB health and repair, it has been 
reported that inhibition of c-Src by siRNA limited permeability of human umbilical 
vein endothelial cells (HUVEC) exposed to vascular endothelial growth factor 
(VEGF, a known inducer of permeability of the BBB; Holmes et al., 2007; Davis 
et al., 2010; Hudson et al., 2014; Cao et al., 2015; Fearnley et al., 2016). In 
addition, chemical inhibition of c-Src with the inhibitor 1-(1,1-dimethylethyl)-3-(4-
methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) accelerated healing of 
wounded HUVEC (Franco et al., 2013), in vitro. Furthermore, in vivo treatment 
with the broad Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)-
pyrazolo[3,4-d]pyrimidine (PP2) in rats subjected to ischemic insult resulted in 
the rescue of ischemic BBB leakage (Takenaga et al., 2009) and improved 
neurological deficit scores (Bai et al., 2014) in the presence of the inhibitor. 
Moreover, c-Src has been identified as an upstream regulator of a number of 
tight junction complex components, including occludin (Takenaga et al., 2009), 
claudin-5 (Bai et al., 2014), and zona occludens-1 (Morin-Brureau et al., 2011), 
as well as a modulator of NMDAR activity in neurons (Lu et al., 1999; Yu and 
Salter, 1999; Rong et al., 2001; Heidinger et al., 2002; Hossain et al., 2012; Tang 
et al., 2012; Krogh et al., 2014), and a downstream effector of the VEGFR2 
signaling pathway (He et al., 1999; Morin-Brureau et al., 2011; Sun et al., 2012; 
Cao et al., 2015), in addition to its role in cell cycle regulation and proliferation 
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(Boggon and Eck, 2004; Parsons and Parsons, 2004; Hu et al., 2008; Sen and 
Johnson, 2011; Reinecke and Caplan, 2014). 
Structurally, c-Src is comprised of several domains, including a 
myristoylated membrane-targeting SH4 domain at the N-terminus, followed by a 
unique domain, a SH3 domain, a SH2 domain, a kinase-linker region, a SH1 
kinase domain bearing the activating tyrosine site (Y416), and a C-terminus 
bearing the inhibiting tyrosine site (Y529) (Boggon and Eck, 2004; Parsons and 
Parsons, 2004; Reinecke and Caplan, 2014). It has been previously reported that 
protein binding of the SH3 domain orchestrates the physical shift necessary to 
induce the active conformation of c-Src (Alexandropoulos and Baltimore, 1996). 
Interestingly, it has previously been shown that HIV-1 Tat binds SH3 domains 
(Rom et al., 2011), and additional results have demonstrated that Tat exposure 
activates c-Src in primary rat neurons (Krogh et al., 2014), in a fetal bovine aortic 
endothelial cell line (Urbinati et al., 2005), and in human renal endothelial cells in 
the presence of growth factors (Das et al., 2016), supporting the hypothesis that 
HIV-1 Tat may delay BBB repair through the activation of c-Src in human 
BMECs. 
In addition, characterization of the ubiquitously-expressed c-Src promotor 
revealed several consensus Sp1 transcription start sites (Bonham and Fujita, 
1993) and further analysis confirmed that transcriptional regulation of c-Src is 
dependent on Sp1 activity at the promotor (Ritchie et al., 2000). The relationship 
of Tat with Sp1 in the transcriptional regulation of the HIV-1 LTR, in addition to 
the regulation of several host genes, has been extensively explored in the 
184 
 
literature (Harrich et al., 1989; Jeang et al., 1993; Majello et al., 1994; Lim and 
Garzino-Demo, 2000; Burnett et al., 2009; Miller-Jensen et al., 2013; Kukkonen 
et al., 2014). In addition, it has been reported that Tat promotes Sp1 
phosphorylation and activity and that this is orchestrated by Tat in a DNA-PK 
(double-stranded DNA-dependent protein kinase)-dependent manner (Chun et 
al., 1998). These reports altogether suggest that Tat may also influence 
expression of c-Src at the transcriptional level by direct modulation of Sp1 activity 
at the c-Src promotor. 
Previous reports have demonstrated that cytosolic c-Src localizes primarily 
with membrane-bound structures (Sen and Johnson, 2011; Reinecke and 
Caplan, 2014), and is documented to associate via adaptor proteins at the 
plasma membrane with both VEGFR2 (Holmes et al., 2007; Sun et al., 2012) and 
NMDAR (Yu and Salter, 1999; Rong et al., 2001; Hossain et al., 2012). VEGFR2 
is a transmembrane receptor tyrosine kinase expressed primarily on vascular 
endothelial cells, including BMECs of the BBB, and is activated by several 
identified ligands collectively termed VEGFs (Holmes et al., 2007; Zhang et al., 
2013; Fearnley et al., 2016). In general, activation of VEGFR2 has been shown 
to induce leakiness of the BBB, both in vivo and in vitro (Davis et al., 2010; 
Hudson et al., 2014). HIV-1 Tat-induced activation of VEGFR2 and related 
endothelial compromise has also been demonstrated (Albini et al., 1996; Ganju 
et al., 1998; Mitola et al., 2000; Arese et al., 2001; Andras et al., 2005). Of note, 
both in vivo and in vitro, VEGFR2 activation has been linked with activation of c-
Src in numerous endothelial cell types (He et al., 1999; Morin-Brureau et al., 
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2011; Sun et al., 2012; Cao et al., 2015), and Tat exposure has been shown to 
mediate VEGFR2-initiated activation of c-Src in endothelial cells (Urbinati et al., 
2005; Das et al., 2016). Taken together, these reports have strongly suggested a 
causal link between Tat exposure, VEGFR2 activation, and c-Src activation in 
endothelial cells of the BBB, which may potentially inhibit BBB repair in patients, 
which has not yet been reported. 
NMDAR is a transmembrane ionotropic glutamate receptor highly 
expressed in the CNS and characterized primarily in neurons (Kopke et al., 1993; 
Lee et al., 2014). Recently, expression of functional NMDAR on BMECs has 
been identified and a demonstration of NMDAR activation resulting in BBB 
compromise has been made in vitro (Sharp et al., 2003, 2005; Andras et al., 
2007; Reijerkerk et al., 2010; Chen et al., 2016). Notably, NMDAR activation is 
itself regulated by c-Src phosphorylation of the NR2 subunits of the NMDAR (Yu 
and Salter, 1999; Rong et al., 2001; Hossain et al., 2012; Tang et al., 2012), and 
exogenous Tat-induced activation of NMDAR in rat neurons, in vitro, has been 
reported (Haughey et al., 2001; Song et al., 2003; Krogh et al., 2014). This 
includes a report that showed Tat-mediated activation of NMDAR in neurons is 
through Tat activation of c-Src (Krogh et al., 2014). In addition to this, a 
reciprocal activation between NMDAR and c-Src has been demonstrated in 
primary rat neuronal cultures. This works through activation of NMDAR which 
causes a Ca2+ influx that activates nitric oxide synthase (NOS) and thus 
generates nitric oxide (NO). This leads to an induction of the S-nitrosylation of c-
Src, which then promotes the auto-phosphorylation of c-Src at the activating 
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tyrosine (Y416), which further phosphorylates the NR2A subunit of NMDAR 
(Tang et al., 2012). All of this is additionally complicated by a report which 
demonstrated HIV-1 Tat subtype-specific toxicity of primary rat neurons and 
NMDAR-expressing HEK cells, wherein markedly decreased cell survival was 
observed in cultures exposed to recombinant subtype B Tat as compared to 
subtype C Tat (Li et al., 2008). These observations were attributed to the 
cysteine to serine variation at position 31 of Tat that has been previously 
documented between these subtypes, and it was determined that this amino acid 
difference influenced the ability of Tat to interact with and activate the NMDAR (Li 
et al., 2008). Taken together, these reports imply an important relationship 
between HIV-1 Tat exposure, Tat genetics, c-Src activation, and NMDAR 
activation in endothelial cells of the BBB, which may hinder BBB repair 
mechanisms, which has not previously been reported. 
In summary, as a dynamic biological structure tasked with mediating 
communication between the CNS and the peripheral circulation, proper 
regulation of the BBB is critical to the maintenance of homeostasis in the CNS, 
and perturbations of the mechanisms in place which maintain this dynamic 
regulation are implicated in the incidence of a number of neurological diseases in 
humans, including HAND. The literature provides evidence that demonstrates 
that BBB damage does indeed occur in HIV-1 CNS disease, and that this 
damage correlates to the spectrum of HAND outcomes reported in patients, 
however, whether these issues are compounded by a mechanistic inhibition of 
BBB repair in these patients, has not yet been documented. In addition, it is 
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unclear as to whether the nature of the damage, the initiator of the damage, and 
whether the precise location or compartment where the damage has occurred 
are of distinct importance in the context of inhibition of the BBB repair 
mechanism proposed herein. Given these observations, understanding how 
extracellular HIV-1 proteins, HIV-1-infected cells, and/or how support cells of the 
BBB (i.e., astrocytes, pericytes) alter the repair of the BBB and whether the 
regulation of c-Src is at the center of this question is an open area of significant 
research to understanding the mechanisms that underlie HIV-1 
neuropathogenesis and HAND (Figure 5.1). 
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Figure 5.1. Hypothetical model of the mechanisms underlying delayed 
blood-brain barrier repair in HIV-1 infection. Differential expression of 
VEGFR2 has been proposed and demonstrated on the lumen- and CNS-
exposed surfaces of primary rat BMECs, in vitro (Hudson et al., 2014), lending to 
the possibility that this receptor may be activated by HIV-1 proteins flowing in the 
peripheral circulation, as well as those generated in the CNS; here, we illustrate 
expression of VEGFR2 on the lumen-exposed surface (orange bubble). 
Polarized expression of NMDAR on BMECs has not been addressed in the 
literature; however, in consideration that the ligands which would activate this 
receptor are readily found in the CNS and secreted by astrocytes (a component 
of the BBB in adjacent proximity with BMECs), we presume and illustrate here 
expression of NMDAR on the CNS-exposed surface (purple bubble). (1) HIV-1 
proteins (Tat, gp120, Vpr, or Nef) bind and activate the VEGFR2 and/or NMDAR, 
stimulating the receptor(s) and resulting in activation of c-Src (which is 
associated with these receptors via adaptor proteins*), leading to a signaling 
cascade which is linked to downregulated expression of tight junction complex 
components (i.e., claudin-5, occludin, and zona occludens-1) and increased 
BBB permeability. (2) HIV-1 Tat protein enters BMECs and traffics to the nucleus 
(by its encoded nuclear localization signal) and upregulates expression of c-Src 
at the transcriptional level via direct modulation of Sp1 activity at the c-Src 
promotor. (3) HIV-1 Tat protein that enters BMECs may also be retained in the 
cytosol and directly bind the SH3 domain of c-Src, thus orchestrating the physical 
shift necessary to induce the active conformation of c-Src (i.e., phosphorylation 
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at Y416 and de-phosphorylation at Y529) and leading to inhibition of BBB repair. 
(4) In addition, there may be super-activation of the NMDAR via a feedback loop 
between the ligand-binding face of NMDAR and cytosolic receptor-associated c-
Src. *Adaptor proteins: VRAP, VEGF receptor associated protein; TSAd, T-cell 
specific adaptor molecule; ND2, NADH dehydrogenase subunit 2. 
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Figure 5.1. 
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